,entities,text,pmid,label
44,methylprednisolone,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,0
47,methylprednisolone,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,0
60,methylprednisolone,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,0
80,selegiline,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,0
81,selegiline,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,0
83,orthostatic hypotension,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,1
84,selegiline,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,0
89,selegiline,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,0
90,orthostatic hypotension,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,1
93,selegiline,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,0
95,orthostatic hypotension,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,1
96,selegiline,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,0
98,orthostatic hypotension,A lesser degree of orthostatic hypotension occurred with standing.,10091617_7,1
99,Orthostatic hypotension,Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.,10091617_8,1
100,selegiline,Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.,10091617_8,0
101,selegiline,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,0
105,selegiline,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,0
107,orthostatic hypotension,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,1
123,platelet aggregation,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,1
129,platelet aggregation,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,1
130,blood coagulation,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,1
133,acetylsalicylic acid,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,0
177,lignocaine,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,0
185,lignocaine,All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.,10225068_1,0
190,lignocaine,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,0
191,neurotoxicity,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,1
193,lignocaine,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,0
194,neurotoxicity,"In the other 3 cases, direct neurotoxicity was also probable, but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology.",10225068_5,1
198,lignocaine,We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg.,10225068_7,0
200,sirolimus,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,0
201,rapamycin,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,0
204,Sirolimus,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0
205,rapamycin,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0
209,sirolimus,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,0
219,sirolimus,"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.",10328196_4,0
221,sirolimus,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,0
249,hypothyroid,"RESULTS: Hypothyroidism developed in 40 patients, excluding 8 patients who were hypothyroid at baseline.",10354657_8,1
282,brain damage,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,1
283,ischemic stroke,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,1
286,ischemic stroke,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,1
288,brain damage,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,1
309,hemolytic anemia,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,1
317,hemolytic anemia,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,1
322,hemolytic anemia,Eight of these cases of severe immune hemolytic anemia are described.,10411803_3,1
333,platelet aggregation,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,1
335,platelet aggregation,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,1
337,platelet aggregation,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,1
359,propofol,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0
363,propofol,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0
364,propofol,We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.,10520387_1,0
366,propofol,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,0
369,propofol,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0
370,propofol,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0
372,propofol,"However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.",10520387_4,0
382,lead acetate,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,0
388,malondialdehyde,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,0
443,Gemcitabine,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0
444,vinorelbine,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0
446,cisplatin,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0
450,vinorelbine,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0
452,gemcitabine,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0
457,cisplatin,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,0
459,cisplatin,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,0
471,neurotoxicity,"Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 neurotoxicity.",10526274_15,1
474,myelosuppression,This age group had an increased risk of myelosuppression.,10526274_19,1
505,creatinine,Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.,10539815_5,0
509,creatinine,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,0
552,olanzapine,Hypomania-like syndrome induced by olanzapine.,10565806_0,0
556,olanzapine,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,0
559,5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,0
572,locomotor hyperactivity,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,1
587,artery calcification,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,1
589,artery calcification,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,1
594,artery calcification,The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.,10669626_1,1
597,artery calcification,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,1
598,artery calcification,"To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.",10669626_4,1
604,artery calcification,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,1
607,artery calcification,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,1
609,artery calcification,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,1
611,artery calcification,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,1
614,artery calcification,This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.,10669626_7,1
616,artery calcification,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,1
626,artery calcification,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,1
629,artery calcification,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,1
635,artery calcification,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,1
681,breast cancer,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,1
682,hemolytic anemia,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,1
684,hemolytic anemia,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,1
716,hemolytic anemia,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,1
772,cardiac hypertrophy,Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.,10721819_3,1
776,bromocriptine,"In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.",10721819_4,0
794,bromocriptine,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,0
823,oral contraceptives,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,0
829,oral contraceptives,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,0
847,hyperalgesia,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,1
851,hyperalgesia,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,1
862,hyperalgesia,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,1
864,hyperalgesia,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,1
865,hyperalgesia,Lidocaine reduced the area of punctate-evoked hyperalgesia significantly.,10743446_8,1
869,hyperalgesia,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,1
870,hyperalgesia,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,1
872,cyclosporine,Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.,10743694_0,0
874,tacrolimus,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,0
878,tacrolimus,"We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.",10743694_2,0
881,tacrolimus,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0
884,tacrolimus,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0
886,neurotoxicity,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
889,nephrotoxicity,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
890,neurotoxicity,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
891,nephrotoxicity,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
892,hepatotoxicity,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
895,hemolytic anemia,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
903,tacrolimus,"When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.",10743694_10,0
906,aggressive behavior,Development of apomorphine-induced aggressive behavior: comparison of adult male and female Wistar rats.,10791295_0,1
909,aggressive behavior,The development of apomorphine-induced (1.0 mg/kg s.c. once daily) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets.,10791295_1,1
912,aggressive behavior,"In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.",10791295_2,1
913,aggressive behavior,"In conclusion, the present study demonstrates gender differences in the development of the apomorphine-induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method.",10791295_4,1
916,rheumatoid arthritis,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,1
917,rheumatoid arthritis,We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.,1079693_1,1
933,cocaine abuse,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,1
937,cocaine abuse,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,1
941,cocaine abuse,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,1
955,nimodipine,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,0
957,Nimodipine,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,0
965,ischemic stroke,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,1
967,nimodipine,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0
969,nimodipine,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0
973,Nimodipine,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,0
997,nimodipine,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,0
999,nimodipine,"For low-dose nimodipine, the results were not conclusive.",10835440_11,0
1001,nimodipine,These results do not confirm or exclude a neuroprotective property of nimodipine.,10835440_12,0
1007,Cyclophosphamide,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,0
1136,Cyclosporine,Cyclosporine and tacrolimus-associated thrombotic microangiopathy.,11007689_0,0
1137,thrombotic microangiopathy,Cyclosporine and tacrolimus-associated thrombotic microangiopathy.,11007689_0,1
1138,thrombotic microangiopathy,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,1
1141,cyclosporine,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,0
1142,cyclosporine,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,0
1150,tacrolimus,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0
1152,cyclosporine,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0
1153,tacrolimus,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,0
1155,tacrolimus,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,0
1159,cyclosporine,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0
1160,tacrolimus,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0
1163,cyclosporine,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,0
1165,tacrolimus,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,0
1169,cyclosporine,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0
1170,tacrolimus,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0
1265,neuropathic pain,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,1
1271,dry mouth,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,1
1285,neuropathic pain,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,1
1287,methylprednisolone,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,0
1292,methylprednisolone,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,0
1297,methylprednisolone,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,0
1298,methylprednisolone,The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition.,11058428_3,0
1307,methylprednisolone,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,0
1309,methylprednisolone,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,0
1311,rapamycin,Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience.,11063349_0,0
1314,cyclosporine,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0
1316,tacrolimus,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0
1319,rapamycin,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,0
1329,hepatotoxicity,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,1
1330,nephrotoxicity,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,1
1331,creatinine,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,0
1355,vigabatrin,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,0
1359,vigabatrin,Six of the patients were no longer receiving vigabatrin.,11077455_3,0
1380,vigabatrin,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,0
1383,vigabatrin,The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.,11077455_12,0
1386,dobutamine,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,0
1388,Dobutamine,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,0
1396,coronary spasm,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,1
1397,dobutamine,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,0
1402,variant angina,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,1
1403,Coronary spasm,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,1
1407,dobutamine,"DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.",11078231_7,0
1414,dobutamine,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,0
1415,coronary spasm,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,1
1420,coronary spasm,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,1
1422,dobutamine,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0
1431,dobutamine,INTERVENTION: Patients underwent dobutamine stress tests per standard protocol.,11079278_5,0
1434,dobutamine,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,0
1445,dobutamine,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,0
1455,parkinsonian,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,1
1463,parkinsonian,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,1
1465,parkinsonian,The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian 'off' signs.,11099450_4,1
1467,parkinsonian,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,1
1469,parkinsonian,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,1
1471,parkinsonian,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,1
1480,Paclitaxel,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0
1481,cisplatin,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0
1482,gemcitabine,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0
1492,paclitaxel,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0
1493,cisplatin,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0
1494,gemcitabine,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0
1501,paclitaxel,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0
1503,cisplatin,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0
1505,gemcitabine,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0
1515,paclitaxel,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0
1516,cisplatin,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0
1517,gemcitabine,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0
1521,paclitaxel,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0
1522,cisplatin,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0
1523,gemcitabine,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0
1532,venlafaxine,This concerns 2 male patients who experienced incontinence while taking venlafaxine.,11147747_3,0
1533,paroxetine,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0
1535,venlafaxine,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0
1557,benzoylecgonine,Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme-mediated immunoassay methodology.,11185967_3,0
1559,benzoylecgonine,Plasma samples with benzoylecgonine greater than 150 ng/mL or an amphetamine greater than 500 ng/mL were defined as positive.,11185967_4,0
1565,benzoylecgonine,"RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.",11185967_6,0
1568,drug abuse,"As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population.",11185967_9,1
1577,zonisamide,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,0
1616,picrotoxin,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,0
1624,adriamycin,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,0
1667,ketamine-,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,0
1672,cardiotoxicity,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,1
1673,cyclophosphamide,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0
1674,cyclophosphamide,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0
1676,breast cancer,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,1
1680,cyclophosphamide,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,0
1683,breast cancer,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,1
1689,cyclophosphamide,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,0
1691,Cardiotoxicity,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,1
1698,cardiotoxicity,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,1
1705,cardiotoxicity,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,1
1707,cyclophosphamide,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,0
1723,cyclophosphamide,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,0
1725,cyclophosphamide,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,0
1727,carboplatin,Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.,11245434_2,0
1731,carboplatin,three times/week starting 7 days before carboplatin application.,11245434_4,0
1732,carboplatin,"Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.",11245434_5,0
1735,carboplatin,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,0
1739,cyclophosphamide,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,0
1748,cyclophosphamide,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,0
1768,losartan,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,0
1772,losartan,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,0
1778,losartan,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,0
1781,losartan,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,0
1789,losartan,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,0
1793,losartan,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,0
1803,polyneuropathy,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,1
1807,cyclosporine-,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0
1808,tacrolimus,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0
1812,cyclosporine,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0
1813,tacrolimus,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0
1819,cyclophosphamide,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,0
1820,cyclophosphamide,Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.,11271907_1,0
1824,cardiotoxicity,Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.,11279304_0,1
1828,cardiotoxicity,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,1
1829,cardiotoxicity,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,1
1830,anthracycline,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,0
1831,cardiac dysfunction,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,1
1836,cardiotoxicity,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,1
1839,daunorubicin,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,0
1862,cardiotoxicity,These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline-induced cardiotoxicity.,11279304_12,1
1956,ventricular tachycardia,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,1
1974,ventricular arrhythmias,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,1
1975,Nephrotoxicity,Nephrotoxicity of combined cephalothin-gentamicin regimen.,1130930_0,1
1977,acute tubular necrosis,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,1
1981,nephrotoxicity,Patients who are given this drug regimen should be observed very carefully for early signs of nephrotoxicity.,1130930_2,1
1987,nephrotoxicity,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,1
1989,cardiotoxicity,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,1
1998,nephrotoxicity,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,1
2001,cardiotoxicity,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,1
2113,thrombotic microangiopathy,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,1
2115,interstitial nephritis,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,1
2116,acute tubular necrosis,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,1
2123,thrombotic microangiopathy,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,1
2164,"(1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine","Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,0
2200,interstitial nephritis,Ranitidine-induced acute interstitial nephritis in a cadaveric renal allograft.,11431197_0,1
2205,interstitial nephritis,This drug occasionally has been associated with acute interstitial nephritis in native kidneys.,11431197_2,1
2207,interstitial nephritis,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,1
2221,hepatotoxicity,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,1
2222,Liver disease,Liver disease caused by propylthiouracil.,1147734_0,1
2225,liver disease,This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease.,1147734_2,1
2228,bupivacaine,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,0
2233,Bupivacaine,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,0
2244,bupivacaine,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,0
2249,bupivacaine,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,0
2253,bupivacaine,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0
2254,cardiac arrest,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,1
2255,bupivacaine,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0
2258,risperidone,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,0
2262,risperidone,The patient developed RS during dose reduction of risperidone.,11532387_3,0
2263,trihexyphenidyl,The symptom was treated successfully with trihexyphenidyl anticholinergic therapy.,11532387_4,0
2265,risperidone,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,0
2271,cisapride,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0
2272,terfenadine,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0
2273,terodiline,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0
2277,ventricular tachycardia,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,1
2283,terfenadine,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,0
2284,terodiline,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,0
2289,terfenadine,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0
2290,terodiline,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0
2291,cisapride,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0
2301,terfenadine,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0
2302,terodiline,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0
2303,cisapride,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0
2307,terfenadine,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0
2308,terodiline,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0
2309,cisapride,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0
2344,Sirolimus,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,0
2349,cyclosporine,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0
2350,tacrolimus,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0
2353,nephrotoxicity,"Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.",11583940_2,1
2354,nephrotoxicity,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,1
2355,nephrotoxicity,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,1
2357,nephrotoxicity,Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases.,11583940_4,1
2360,sirolimus,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0
2361,rapamycin,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0
2362,nephrotoxicity,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,1
2388,citalopram,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,0
2389,major depression,Current estimates suggest that between 0.4% and 8.3% of children and adolescents are affected by major depression.,11642480_1,1
2391,citalopram,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,0
2392,major depression,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,1
2395,citalopram,This may have been a side effect of citalopram as it remitted with redistribution of doses.,11642480_3,0
2396,sulphasalazine,The 3-week sulphasalazine syndrome strikes again.,11672959_0,0
2397,sulphasalazine,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,0
2399,rheumatoid arthritis,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,1
2417,sulphasalazine,"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week sulphasalazine syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine.",11672959_6,0
2419,sulphasalazine,"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week sulphasalazine syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine.",11672959_6,0
2452,paracetamol,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,0
2455,paracetamol,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,0
2460,paracetamol,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,0
2462,paracetamol,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,0
2465,paracetamol,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,0
2468,paracetamol,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,0
2471,paracetamol,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,0
2475,paracetamol,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,0
2507,hemolytic anemia,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,1
2520,hemolytic anemia,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,1
2551,mitochondrial dysfunction,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,1
2579,cisplatin,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0
2581,amifostine,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0
2582,breast carcinoma,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,1
2584,Cisplatin,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0
2587,breast carcinoma,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,1
2590,cisplatin,Older reports suggest an objective response rate of 8% when 60-120 mg/m2 of cisplatin is administered every 3-4 weeks.,11745184_1,0
2592,cisplatin,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0
2594,cisplatin,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0
2595,nephrotoxicity,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,1
2596,ototoxicity,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,1
2597,neurotoxicity,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,1
2598,breast carcinoma,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,1
2600,amifostine,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,0
2603,Amifostine,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0
2606,cisplatin,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0
2608,cisplatin,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,0
2609,amifostine,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,0
2610,nephrotoxicity,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,1
2611,ototoxicity,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,1
2613,cisplatin,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,0
2614,amifostine,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,0
2615,breast carcinoma,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,1
2618,amifostine,"Patients received amifostine, 910 mg/m2 intravenously over 15 minutes.",11745184_7,0
2619,amifostine,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0
2620,cisplatin,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0
2623,cisplatin,Intravenous hydration and mannitol was administered before and after cisplatin.,11745184_9,0
2630,cisplatin,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0
2631,amifostine,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0
2635,amifostine,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0
2636,cisplatin,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0
2637,Oral contraceptives,Oral contraceptives and the risk of myocardial infarction.,11752354_0,0
2639,oral contraceptives,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,0
2643,desogestrel,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0
2647,oral contraceptives,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0
2663,oral contraceptive,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,0
2668,oral contraceptives,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0
2670,oral contraceptives,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0
2671,oral contraceptives,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,0
2677,oral contraceptives,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,0
2678,oral contraceptives,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0
2680,oral contraceptives,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0
2682,oral contraceptives,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,0
2702,hyperalgesia,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,1
2707,hyperalgesia,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,1
2715,neuropathic pain,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,1
2717,End-stage renal disease,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,1
2723,tacrolimus,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,0
2728,end-stage renal disease,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,1
2732,chronic renal failure,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,1
2739,creatinine,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,0
2745,renal dysfunction,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,1
2751,creatinine,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0
2753,creatinine,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0
2755,creatinine,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,0
2774,creatinine,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,0
2776,creatinine,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,0
2816,thromboembolic,PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.,11827497_6,1
2821,thromboembolic,"RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.",11827497_8,1
2838,hyperprolactinemia,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,1
2840,Risperidone,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,0
2845,hyperprolactinemia,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,1
2852,hyperprolactinemia,These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.,11838826_3,1
2854,hyperprolactinemia,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,1
2857,hyperprolactinemia,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,1
2874,risperidone,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,0
2880,hyperprolactinemia,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,1
2899,metoclopramide,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,0
2903,metoclopramide,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0
2906,procainamide,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0
2909,metoclopramide,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,0
2911,cisapride,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,0
2914,metoclopramide,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,0
2916,Metoclopramide,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,0
2924,neurotoxicity,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,1
2930,neurotoxicity,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,1
2995,cardiotoxicity,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,1
2997,anthracycline,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,0
3000,cardiotoxicity,"Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.",11861791_3,1
3008,cardiac dysfunction,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,1
3021,cardiac dysfunction,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,1
3027,cardiotoxicity,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,1
3034,Nephrotoxicity,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,1
3055,exencephaly,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,1
3057,exencephaly,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,1
3058,exencephaly,"Anencephaly has been suggested to develop from exencephaly; however, there is little direct experimental evidence to support this, and the mechanism of transformation remains unclear.",11875660_1,1
3061,exencephaly,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,1
3062,5-azacytidine,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,0
3065,exencephaly,We confirmed several cases of transformation from exencephaly to anencephaly.,11875660_4,1
3066,exencephalic,"However, in many cases, the exencephalic brain tissue was preserved with more or less reduction during this period.",11875660_5,1
3067,exencephaly,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,1
3068,exencephalic,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,1
3070,exencephalic,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,1
3071,exencephalic,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,1
3074,exencephaly,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,1
3078,exencephalic,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,1
3080,exencephalic,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,1
3082,exencephalic,"From observations of the vasculature, altered distribution patterns of vessels were identified in the exencephalic head.",11875660_9,1
3083,exencephalic,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,1
3086,exencephalic,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,1
3088,exencephaly,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,1
3093,6-hydroxydopamine,Erectile function was assessed 6 weeks following uni- and bilateral injections of 6-hydroxydopamine in the substantia nigra nucleus of the brain.,11890511_1,0
3109,acute myocardial infarction,Infarct-avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction.,11897407_1,1
3118,acute myocardial infarction,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,1
3133,hexamethonium,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0
3135,hexamethonium,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0
3139,hexamethonium,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,0
3179,Bupropion,Bupropion (Zyban) toxicity.,11928786_0,0
3181,Bupropion,Bupropion is a monocyclic antidepressant structurally related to amphetamine.,11928786_1,0
3185,bupropion,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,0
3187,cardiac arrhythmias,"Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest.",11928786_6,1
3188,cardiac arrest,"Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest.",11928786_6,1
3191,bupropion,"We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion.",11928786_8,0
3221,glomerulosclerosis,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,1
3283,risperidone,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,0
3285,risperidone,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,0
3287,Risperidone,Risperidone administration was continued and the visual disturbances gradually wore off.,12013711_4,0
3293,risperidone,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,0
3297,aplastic anemia,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,1
3300,aplastic anemia,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,1
3306,aplastic anemia,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,1
3309,metabolic acidosis,Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.,12042105_2,1
3342,Ifosfamide,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,0
3343,Ifosfamide,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,0
3344,asterixis,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,1
3346,ifosfamide,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,0
3350,ifosfamide,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,0
3359,ifosfamide,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,0
3360,asterixis,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,1
3361,asterixis,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,1
3362,ifosfamide,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,0
3369,Azidothymidine,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0
3425,glycopyrrolate,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,0
3436,glycopyrrolate,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,0
3466,nephrotoxicity,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,1
3508,cardiac arrest,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,1
3512,paracetamol,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,0
3523,cardiac arrest,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,1
3547,thromboembolic,Data to establish the thromboembolic risk were incomplete.,12109865_8,1
3563,Cardiac arrest,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,1
3564,metoclopramide,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,0
3565,metoclopramide,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,0
3566,cardiac arrest,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,1
3568,metoclopramide,We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.,12139551_1,0
3569,metoclopramide,The patient received metoclopramide 10 mg i.v.,12139551_2,0
3572,metoclopramide,"five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.",12139551_3,0
3575,cardiac arrest,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,1
3576,metoclopramide,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,0
3629,carbachol,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,0
3636,carbachol,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,0
3711,locomotor hyperactivity,Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.,12369736_0,1
3716,locomotor hyperactivity,The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.,12369736_1,1
3731,locomotor hyperactivity,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,1
3803,rizatriptan,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,0
3805,Rizatriptan,Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.,12464714_1,0
3810,rizatriptan,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,0
3813,rizatriptan,"Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001).",12464714_3,0
3815,rizatriptan,"Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.",12464714_4,0
3818,rizatriptan,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,0
3819,rizatriptan,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,0
3822,rizatriptan,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,0
3823,rizatriptan,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,0
3825,rizatriptan,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,0
3827,rizatriptan,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,0
3830,Rizatriptan,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,0
3834,rizatriptan,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,0
3837,rizatriptan,Recurrence rates were 31.4% with rizatriptan and 15.3% with ergotamine/caffeine.,12464714_11,0
3841,rizatriptan,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,0
3867,carboplatin,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,0
3875,carboplatin,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0
3877,cisplatin,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0
3879,carboplatin,"However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.",12483326_5,0
3881,carboplatin,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,0
3895,carboplatin,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,0
3897,Visual hallucinations,Visual hallucinations associated with zonisamide.,12523465_0,1
3899,zonisamide,Visual hallucinations associated with zonisamide.,12523465_0,0
3900,Zonisamide,Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.,12523465_1,0
3902,visual hallucinations,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,1
3904,visual hallucinations,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,1
3906,zonisamide,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,0
3907,visual hallucinations,"During monitoring, visual hallucinations did not correlate with EEG readings, nor did video recording capture any of the described events.",12523465_4,1
3908,visual hallucinations,None of the patients had experienced visual hallucinations before this event.,12523465_5,1
3909,zonisamide,The only recent change in their treatment was the introduction or increased dosage of zonisamide.,12523465_6,0
3912,zonisamide,"Until then, clinicians need to be aware of this possible complication associated with zonisamide.",12523465_9,0
3915,carbamazepine,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0
3916,vigabatrin,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0
3926,Acute liver failure,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,1
3927,bupropion,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,0
3928,carbimazole,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,0
3931,bupropion,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,0
3932,carbimazole,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,0
3935,carbimazole,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,0
3936,propranolol,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,0
3937,bupropion,He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.,12549952_3,0
3938,acute liver failure,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,1
3941,liver injury,Liver biopsy showed evidence of nonspecific drug-induced acute liver injury.,12549952_5,1
3943,coagulopathy,His condition was further complicated by sepsis and coagulopathy.,12549952_6,1
3945,bupropion,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,0
3946,hepatotoxicity,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,1
3948,hepatotoxicity,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,1
3949,bupropion,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0
3950,acute liver failure,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,1
3951,bupropion,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0
3952,carbimazole,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0
3954,bupropion,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,0
3974,iodixanol,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0
3978,creatinine,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,0
3983,creatinine,The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.,12571256_5,0
3984,creatinine,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0
3985,creatinine,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0
3986,creatinine,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,0
3988,iodixanol,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,0
3990,creatinine,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0
3991,iodixanol,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0
3993,iodixanol,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0
3996,iodixanol,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0
3997,creatinine,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0
4000,iodixanol,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0
4003,iodixanol,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,0
4005,creatinine,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0
4006,iodixanol,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0
4008,iodixanol,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0
4012,iodixanol,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,0
4015,renal injury,Prenatal dexamethasone programs hypertension and renal injury in the rat.,12574103_0,1
4018,renal injury,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,1
4028,glomerulosclerosis,Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.,12574103_7,1
4031,glomerulosclerosis,"This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.",12574103_8,1
4036,cyclosporine,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0
4037,tacrolimus,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0
4038,sirolimus,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0
4039,Sirolimus,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,0
4050,cyclosporine,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0
4052,tacrolimus,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0
4095,myocardial damage,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,1
4104,myocardial damage,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,1
4151,myocardial damage,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,1
4165,cardiotoxicity,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,1
4168,pulmonary hypertension,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,1
4173,Pulmonary hypertension,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,1
4175,octreotide,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,0
4212,oral contraceptives,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,0
4244,nephrotoxicity,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,1
4252,Nephrotoxicity,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,1
4253,creatinine,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0
4254,glutathione,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0
4259,creatinine,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0
4264,tubular necrosis,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,1
4270,chronic renal failure,"Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure, and on the mechanism(s) involved.",12617329_6,1
4273,docetaxel,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,0
4274,prostate cancer,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,1
4277,prostate cancer,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,1
4279,docetaxel,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,0
4283,prostate cancer,"PATIENTS: Seventy men, aged 50-80 years, with advanced androgen-independent prostate cancer.",12627929_4,1
4284,docetaxel,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0
4286,docetaxel,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0
4289,docetaxel,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0
4291,docetaxel,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0
4293,docetaxel,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,0
4294,prostate cancer,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,1
4298,ticlopidine,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,0
4302,ticlopidine,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,0
4306,ticlopidine,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,0
4308,ticlopidine,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,0
4313,ticlopidine,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,0
4316,hepatotoxicity,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,1
4319,ticlopidine,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,0
4323,ticlopidine,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0
4325,clopidogrel,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0
4365,vigabatrin,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,0
4373,visual field defects,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,1
4396,dystonia,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,1
4403,dystonia,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,1
4409,neurotoxicity,MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.,12695819_0,1
4414,tacrolimus,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,0
4417,tacrolimus,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,0
4427,neurotoxicity,Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus-induced neurotoxicity.,12695819_8,1
4431,Hydrocortisone acetate,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,0
4487,myocardial injury,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,1
4489,myocardial injury,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,1
4492,myocardial injury,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,1
4502,cyclophosphamide,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,0
4521,bupropion,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,0
4524,bupropion,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,0
4528,bupropion,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,0
4530,bupropion,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,0
4540,17beta-estradiol,We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.,12757899_2,0
4543,17beta-estradiol,Rats received subcutaneous injections of 17beta-estradiol (2 microg/rat) or oil once daily for four consecutive days.,12757899_3,0
4547,17beta-Estradiol,17beta-Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males.,12757899_6,0
4549,17beta-Estradiol,17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats.,12757899_7,0
4587,prostate cancer,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,1
4588,prostate cancer,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,1
4616,prostate cancer,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,1
4628,prostate cancer,CONCLUSION: Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,12820454_14,1
4631,neurotoxicity,Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.,12842176_0,1
4679,oral contraceptives,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0
4704,acetylsalicylic acid,Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.,12852481_0,0
4707,acetylsalicylic acid,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,0
4849,interstitial nephritis,Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.,12911170_0,1
4850,autoimmune hemolytic anemia,Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.,12911170_0,1
4853,interstitial nephritis,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,1
4854,hemolytic anemia,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,1
4856,interstitial nephritis,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,1
4857,autoimmune hemolytic anemia,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,1
4858,Hemolytic anemia,Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.,12911170_4,1
4859,interstitial nephritis,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,1
4860,end-stage renal disease,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,1
4865,gamma-aminobutyric acid,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0
4902,creatinine,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0
4914,blood coagulation,Progestational agents and blood coagulation.,133615_0,1
4915,Thromboembolic,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,1
4916,oral contraceptive,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,0
4921,oral contraceptives,"During a ten-year period, 348 women were studied for a total of 5,877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters.",133615_3,0
4922,blood coagulation,"Significant increases in certain factors of the blood coagulation and fibrinolysin systems (factors I,II,VII,VIII,IX, and X and plasminogen) were observed in the treated groups.",133615_4,1
4925,blood coagulation,"All four had an abnormal blood coagulation profile, suggesting ""hypercoagulability"" before initiation of therapy.",133615_6,1
4932,thromboembolic,Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen.,133615_12,1
4935,oral contraceptive,It appears from these data that hematologic work-ups may be useful in women who are about to start long-term oral contraceptive therapy.,133615_13,0
4936,Orthostatic hypotension,Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.1.,1355091_0,1
4946,Orthostatic hypotension,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,1
4954,orthostatic hypotension,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,1
4967,orthostatic hypotension,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,1
5019,chronic renal failure,Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.,1378968_0,1
5038,glomerulosclerosis,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,1
5042,creatinine,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,0
5052,chronic renal failure,"In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli.",1378968_11,1
5060,Hemolytic-uremic syndrome,Hemolytic-uremic syndrome associated with ingestion of quinine.,1415380_0,1
5062,Hemolytic-uremic syndrome,"Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature.",1415380_1,1
5064,dipyridamole,"Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole.",1415380_4,0
5068,hemolytic-uremic syndrome,Quinine-associated hemolytic-uremic syndrome probably occurs more often than is recognized.,1415380_7,1
5106,sexual dysfunction,Depression and sexual dysfunction have been related to side effects of topical beta-blockers.,1428568_1,1
5125,neurotoxicity,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,1
5128,amino acid,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,0
5158,hemolytic anemia,Cefotetan-induced immune hemolytic anemia.,1445986_0,1
5159,hemolytic anemia,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,1
5169,hemolytic anemia,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,1
5173,ketoconazole,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,0
5174,ketoconazole,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,0
5179,parkinsonian,Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.,14568327_0,1
5224,mesna,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,0
5229,ifosfamide,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,0
5231,mesna,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,0
5236,mesna,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,0
5238,mesna,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0
5239,mesna,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0
5243,mesna,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,0
5247,mesna,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0
5248,mesna,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0
5249,mesna,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,0
5252,mesna,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0
5253,mesna,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0
5282,dilated cardiomyopathy,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,1
5284,dilated cardiomyopathy,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,1
5297,5-hydroxytriptamine,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0
5313,cyclophosphamide,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,0
5327,psychotic symptoms,"This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.",14698717_3,1
5340,carbamazepine,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,0
5344,bicuculline,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,0
5350,bicuculline,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0
5397,sexual dysfunction,"A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.",14742097_0,1
5400,sexual dysfunction,"The objective of this study was to determine whether ephedrine, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced sexual dysfunction.",14742097_1,1
5402,paroxetine,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,0
5417,breast cancer,Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition?,14745746_0,1
5422,breast cancer,This pilot study examines whether hormone therapy for breast cancer affects cognition.,14745746_2,1
5425,breast cancer,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,1
5436,breast cancer,The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer.,14745746_6,1
5509,propranolol,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,0
5511,propranolol,"Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.",14982270_5,0
5538,hexamethonium,These responses were blocked by systemic pre-administration of hexamethonium chloride (20 mg/kg).,15009014_6,0
5594,cardiac arrhythmias,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,1
5596,cardiac toxicity,The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.,15042318_2,1
5604,liver injury,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,1
5606,liver injury,PATIENT: A 58-year-old woman with a clinical diagnosis of dilevalol-induced liver injury.,1504402_2,1
5622,liver injury,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,1
5719,temporal lobe epilepsy,Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy.,15120741_0,1
5730,bicuculline,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,0
5744,temporal lobe epilepsy,"These data support the hypothesis that SE-induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains, resembling rat models of human temporal lobe epilepsy.",15120741_6,1
5745,bladder cancer,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,1
5747,cyclophosphamide,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,0
5748,bladder cancer,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,1
5749,cyclophosphamide,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,0
5753,bladder cancer,"Through linkage with the Swedish Cancer Register, all subjects in this cohort diagnosed with bladder cancer were identified.",15130900_3,1
5755,cyclophosphamide,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,0
5756,bladder cancer,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,1
5759,bladder cancer,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,1
5762,bladder cancer,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,1
5764,cyclophosphamide,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,0
5765,bladder cancer,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,1
5766,cyclophosphamide,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,0
5770,bladder cancer,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,1
5772,bladder cancer,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,1
5775,cyclophosphamide,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,0
5776,bladder cancer,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,1
5788,alpha-methyldopa,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,0
5809,alpha-methyldopa,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,0
5814,alpha-methyldopa,SDRR was reduced only by alpha-methyldopa.,15145918_6,0
5816,alpha-methyldopa,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,0
5822,17beta-estradiol,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,0
5827,alpha-methyldopa,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,0
5868,thrombotic,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,1
5869,thrombotic,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,1
5874,rheumatoid arthritis,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,1
5877,thrombotic,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,1
5879,thrombotic,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,1
5881,diclofenac,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,0
5883,rheumatoid arthritis,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,1
5887,thrombotic,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,1
5888,thrombotic,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,1
5889,Thrombotic,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,1
5897,thrombotic,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,1
5899,rheumatoid arthritis,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,1
5904,dobutamine,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,0
5908,mitral regurgitation,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,1
5910,dobutamine,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,0
5915,lignocaine,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,0
5921,lignocaine,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,0
5974,sevoflurane,The effects of sevoflurane on lidocaine-induced convulsions.,15278670_0,0
5975,sevoflurane,The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.,15278670_1,0
5979,sevoflurane,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,0
5981,sevoflurane,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0
5982,sevoflurane,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0
5984,sevoflurane,There was no significant difference in the convulsive threshold between sevoflurane and enflurane.,15278670_4,0
5986,sevoflurane,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0
5988,sevoflurane,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0
5993,sevoflurane,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,0
5999,sevoflurane,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,0
6001,Cardiac toxicity,Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.,15325671_0,1
6003,breast cancer,Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.,15325671_0,1
6004,Cyclophosphamide,INTRODUCTION: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens.,15325671_1,0
6009,paclitaxel,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0
6010,cyclophosphamide,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0
6011,carboplatin,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0
6014,breast cancer,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,1
6015,breast cancer,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,1
6016,cyclophosphamide,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,0
6028,cyclophosphamide,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,0
6030,cardiac toxicity,Incidence of transient cyclophosphamide-related cardiac toxicity (10%) is comparable to previous recorded literature.,15325671_6,1
6037,cyclophosphamide,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,0
6039,salbutamol,"Tremor side effects of salbutamol, quantified by a laser pointer technique.",15338796_0,0
6042,salbutamol,"OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.",15338796_1,0
6049,salbutamol,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,0
6056,Salbutamol,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,0
6062,Yohimbine,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,0
6065,yohimbine,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,0
6068,yohimbine,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,0
6070,yohimbine,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,0
6074,yohimbine,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,0
6076,yohimbine,Various doses of yohimbine were used to determine the ideal dose for each patient.,1535072_6,0
6079,yohimbine,RESULTS: Five of the six patients experienced improved sexual functioning after taking yohimbine.,1535072_7,0
6080,yohimbine,One patient who failed to comply with yohimbine treatment had no therapeutic effects.,1535072_8,0
6083,yohimbine,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,0
6084,yohimbine,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,0
6087,yohimbine,Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication.,1535072_11,0
6091,cyclophosphamide,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,0
6098,mesna,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0
6100,cyclophosphamide,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0
6119,gallbladder disease,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,1
6131,gallbladder disease,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,1
6135,endometrial cancer,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,1
6140,gallbladder disease,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,1
6142,endometrial cancer,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,1
6154,orthostatic hypotension,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,1
6169,desferrioxamine,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,0
6171,sensorineural hearing loss,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,1
6187,cardiotoxicity,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,1
6197,cardiac toxicity,The number of deaths related to cardiac toxicity is low.,15517007_6,1
6198,cyclophosphamide,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0
6200,mitoxantrone,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0
6296,renal damage,Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage.,15572383_0,1
6302,renal damage,"Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats.",15572383_3,1
6303,adriamycin,"Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats.",15572383_3,0
6309,adriamycin,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,0
6310,adriamycin,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,0
6311,nephrotic,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,1
6313,glomerulosclerosis,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,1
6314,adriamycin,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0
6321,glomerulosclerosis,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,1
6324,renal damage,CONCLUSION: Individual differences in renal ACE activity predict the severity of adriamycin-induced renal damage in this outbred rat strain.,15572383_13,1
6327,renal damage,This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage.,15572383_14,1
6353,Hemolytic anemia,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,1
6356,hemolytic anemia,"Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.",15580403_1,1
6380,interstitial nephritis,Recurrent acute interstitial nephritis induced by azithromycin.,15602202_0,1
6386,interstitial nephritis,"Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.",15602202_3,1
6387,renal injury,"Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.",15602202_3,1
6413,creatinine,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,0
6421,hyperprolactinemia,Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.,15638391_0,1
6422,hyperprolactinemia,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,1
6483,Reserpine-,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,0
6552,pseudolithiasis,Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.,15737522_0,1
6554,pseudolithiasis,It is well known that ceftriaxone leads to pseudolithiasis in some patients.,15737522_1,1
6557,pseudolithiasis,"Clinical and experimental studies also suggest that situations causing gallbladder dysfunction, such as fasting, may have a role for the development of pseudolithiasis.",15737522_2,1
6558,pseudolithiasis,"In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.",15737522_3,1
6563,pseudolithiasis,"Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age, sex, duration of the treatment and starvation variables.",15737522_5,1
6565,pseudolithiasis,"After cessation of the treatment, pseudolithiasis resolved spontaneously within a short period.",15737522_6,1
6566,pseudolithiasis,The incidence of pseudolithiasis is not affected by fasting.,15737522_7,1
6571,psychotic symptoms,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,1
6572,amphetamine-,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,0
6577,psychotic symptoms,"Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and stereotypies appears to be at least in part dose-related.",15764424_4,1
6670,hepatotoxicity,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,1
6686,hepatotoxicity,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,1
6699,thrombotic microangiopathy,Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation.,15859940_0,1
6701,Thrombotic microangiopathy,OBJECTIVES: Thrombotic microangiopathy is a well-known problem in patients following renal transplantation.,15859940_1,1
6704,thrombotic microangiopathy,"In postrenal transplantation, thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome.",15859940_2,1
6705,hemolytic uremic syndrome,"In postrenal transplantation, thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome.",15859940_2,1
6706,thrombotic microangiopathy,We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature.,15859940_3,1
6708,thrombotic microangiopathy,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,1
6713,thrombotic microangiopathy,RESULTS: Five cases of thrombotic microangiopathy were found.,15859940_6,1
6715,cyclosporine,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0
6716,cyclosporine,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0
6717,tacrolimus,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0
6718,thrombotic microangiopathy,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,1
6722,hemolytic uremic syndrome,"CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome.",15859940_10,1
6724,hemolytic uremic syndrome,"CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome.",15859940_10,1
6726,cyclosporine,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0
6727,tacrolimus,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0
6731,thrombotic microangiopathy,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,1
6733,cyclosporine,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,0
6734,thrombotic microangiopathy,"In the current study, the frequency of thrombotic microangiopathy was similar to the percentage reported in the literature (20%).",15859940_13,1
6815,propofol,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,0
6818,myelosuppression,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,1
6820,etoposide,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0
6821,daunorubicin,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0
6826,myelosuppression,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,1
6827,cardiac toxicity,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,1
6829,cardiotoxicity,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,1
6834,etoposide,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0
6835,daunorubicin,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0
6841,etoposide,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0
6842,daunorubicin,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0
6847,myelosuppression,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,1
6849,daunorubicin,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0
6850,etoposide,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0
6854,myelosuppression,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,1
6860,daunorubicin,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,0
6862,etoposide,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,0
6867,etoposide,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,0
6897,benzoylecgonine,Seizures induced by the cocaine metabolite benzoylecgonine in rats.,1592014_0,0
6900,benzoylecgonine,"We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.",1592014_3,0
6910,cocaine-,"The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.",1592014_10,0
6913,propofol,Assessment of the onset and persistence of amnesia during procedural sedation with propofol.,15930398_0,0
6916,propofol,"OBJECTIVES: To assess patients' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol, and correlate their recall with their level of awareness as measured by bispectral index (BIS) monitoring.",15930398_1,0
6920,propofol,"METHODS: This was a prospective, single-intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28, 2002, and October 31, 2003.",15930398_2,0
6984,hyperalgesia,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,1
6986,hyperalgesia,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,1
6992,methylprednisolone,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0
7052,myocardial injury,Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers.,1601297_0,1
7055,myocardial injury,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,1
7126,paclitaxel,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0
7127,carboplatin,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0
7133,paclitaxel,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,0
7134,carboplatin,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,0
7135,paclitaxel,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,0
7137,paclitaxel,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,0
7151,myoclonic jerks,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,1
7283,hyperammonemia,It is usually but not necessarily associated with hyperammonemia.,16181582_3,1
7310,risperidone,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,0
7311,olanzapine,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,0
7351,Aminoglycoside,Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost.,16298782_2,0
7352,ototoxicity,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,1
7355,sensorineural hearing loss,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,1
7401,secondary hyperalgesia,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,1
7402,Secondary hyperalgesia,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,1
7404,hyperalgesia,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,1
7405,neuropathic pain,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,1
7408,hyperalgesia,Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization.,16330766_3,1
7413,neuropathic pain,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,1
7423,secondary hyperalgesia,"Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.",16330766_5,1
7453,temporal lobe epilepsy,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,1
7538,nitrendipine,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,0
7539,nitrendipine,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,0
7556,nitrendipine,Enalapril but not nitrendipine reduced blood pressure significantly.,1639466_6,0
7560,glomerulosclerosis,"Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.",1639466_8,1
7564,glomerulosclerosis,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,1
7576,Ketoconazole,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,0
7580,Ketoconazole,Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval-prolonging drugs.,16403073_1,0
7587,ketoconazole,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,0
7589,ketoconazole,Her QT interval returned to normal upon withdrawal of ketoconazole.,16403073_3,0
7593,ketoconazole,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,0
7596,ketoconazole,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,0
7669,dry mouth,Only one case (3.3%) withdrew from the present study due to a severe dry mouth.,16471092_10,1
7717,DEX,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,0
7724,"3,4-methylenedioxymethamphetamine","Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,0
7751,memory impairment,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,1
7774,myocardial damage,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,1
7792,glutathione,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
7900,hepatocellular carcinoma,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,1
7901,liver disease,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,1
7906,hemolytic anemia,"Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.",16629641_3,1
7913,hemolytic anemia,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,1
7930,drug abuse,Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse.,16634859_8,1
7963,cinacalcet,OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6.,16680561_1,0
7965,cinacalcet,"The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.",16680561_2,0
7975,cinacalcet,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,0
7981,cinacalcet,"Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.",16680561_6,0
7982,cinacalcet,"The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).",16680561_7,0
7986,cinacalcet,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0
7988,cinacalcet,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0
7989,cinacalcet,CONCLUSION: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6.,16680561_10,0
7991,cinacalcet,"These data suggest that during concomitant treatment with cinacalcet, dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6.",16680561_11,0
7997,visual loss,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,1
8015,visual loss,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,1
8023,paroxetine,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,0
8027,paroxetine,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,0
8028,paroxetine,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,0
8032,extrapyramidal symptoms,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,1
8034,aspartate,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0
8035,bromocriptine,The patient received bromocriptine and diazepam to treat his symptoms.,16720068_6,0
8040,paroxetine,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,0
8057,bupivacaine,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,0
8075,carbachol,Case report: acute unintentional carbachol intoxication.,16740173_0,0
8076,carbachol,"INTRODUCTION: Intoxications with carbachol, a muscarinic cholinergic receptor agonist are rare.",16740173_1,0
8085,carbachol,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,0
8086,carbachol,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,0
8087,Carbachol,Carbachol concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry.,16740173_6,0
8109,carbachol,"Serum samples from the first and second days contained 3.6 and 1.9 mg/l carbachol, respectively.",16740173_18,0
8117,carbachol,"For the first time, an analytical method for the determination of carbachol in plasma and urine has been developed.",16740173_21,0
8118,carbachol,The analysed carbachol concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260.,16740173_22,0
8135,Diazepam-,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,0
8136,scopolamine-,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,0
8165,bone marrow suppression,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,1
8166,hepatotoxicity,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,1
8168,hyperammonemia,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,1
8176,Dex,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,0
8182,dex,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,0
8186,dex,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,0
8193,dex,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,0
8196,dex,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,0
8202,Peripheral neuropathy,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,1
8217,peripheral neuropathy,Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.,16826348_5,1
8221,methylprednisolone,"This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.",16826348_6,0
8222,peripheral neuropathy,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,1
8227,deferoxamine,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,0
8229,neurotoxicity,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,1
8236,deferoxamine,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0
8239,neurotoxicity,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,1
8251,glutathione,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,0
8258,neuronal damage,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,1
8260,Cerebral haemorrhage,Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions.,16858720_0,1
8266,cerebral haemorrhage,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,1
8269,cerebral haemorrhage,Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.,16858720_2,1
8271,cerebral haemorrhage,"RESULTS: Among 593 patients with cerebral haemorrhage, 59 (10%) were assessed as related to warfarin treatment.",16858720_4,1
8326,sulpiride,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,0
8327,sulpiride,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,0
8330,sulpiride,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,0
8336,sulpiride,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,0
8353,bupivacaine,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,0
8362,bupivacaine,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.",16904497_7,0
8363,triamcinolone diacetate,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.",16904497_7,0
8398,hepatocellular carcinoma,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,1
8422,ventricular arrhythmias,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,1
8426,ouabain,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,0
8480,clopidogrel,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,0
8496,extrapyramidal symptoms,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,1
8501,extrapyramidal symptoms,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,1
8519,Extrapyramidal symptoms,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,1
8595,Dex,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,0
8601,Dex,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0
8607,Dex,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0
8611,Dex,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0
8613,Dex,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0
8614,Dex,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,0
8617,Dex,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,0
8634,amino acid,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,0
8651,paroxetine,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,0
8656,sodium citrate,The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.,17111419_8,0
8693,renal dysfunction,Sirolimus-associated proteinuria and renal dysfunction.,17147461_0,1
8694,Sirolimus,Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase.,17147461_1,0
8697,rapamycin,Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase.,17147461_1,0
8698,Sirolimus,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,0
8702,sirolimus,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,0
8707,sirolimus,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,0
8711,renal damage,A common risk factor appears to be presence of pre-existing chronic renal damage.,17147461_6,1
8714,sirolimus,"It has also been suggested that sirolimus directly causes increased glomerular permeability/injury, but evidence for this mechanism is currently inconclusive.",17147461_8,0
8718,sirolimus,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,0
8724,sirolimus,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0
8725,sirolimus,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0
8731,sirolimus,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,0
8734,sirolimus,Proteinuria after conversion to sirolimus in renal transplant recipients.,17175308_0,0
8736,Sirolimus,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,0
8740,sirolimus,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,0
8755,nephrotic,Twenty-eight percent of patients showed increased proteinuria to the nephrotic range.,17175308_11,1
8757,interstitial nephritis,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,1
8759,creatinine,Serum creatinine values did not change significantly: 1.98 +/-,17175308_14,0
8767,creatinine,"Mean serum creatinine level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02).",17175308_19,0
8811,aggressive behavior,"Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.",17194457_12,1
8817,ifosfamide,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,0
8822,ifosfamide,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0
8823,ifosfamide,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0
8825,cisplatin,None of them had received cisplatin chemotherapy.,1720453_3,0
8830,creatinine,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0
8841,ifosfamide,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,0
8845,ifosfamide,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,0
8902,temporal lobe epilepsy,"QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.",17242861_3,1
8918,temporal lobe epilepsy,This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy.,17242861_11,1
8954,carbachol,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,0
8999,Cardiac arrest,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,1
9001,sevoflurane,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,0
9010,cardiac arrest,There are no previous reports of clonidine-associated cardiac arrest in a child undergoing induction of anesthesia.,17263743_5,1
9034,liver injury,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,1
9041,cardiac dysfunction,Carbamazepine-induced cardiac dysfunction.,1728915_0,1
9043,sinus bradycardia,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,1
9045,carbamazepine,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,0
9047,cardiac dysfunction,"From the analysis of these cases, two distinct forms of carbamazepine-associated cardiac dysfunction emerged.",1728915_3,1
9054,carbamazepine,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,0
9055,carbamazepine,"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.",1728915_6,0
9056,Dobutamine,Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.,1732369_0,0
9065,dobutamine,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,0
9072,dobutamine,"Graded dobutamine infusions of 0.5, 2.5, 5 and 10 micrograms/kg per min were administered.",1732369_4,0
9075,Dobutamine,Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms.,1732369_6,0
9083,dobutamine,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,0
9090,dobutamine,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,0
9102,adriamycin,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,0
9115,adriamycin,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,0
9182,hypothyroid,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,1
9200,terbutaline,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,0
9208,Terbutaline,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,0
9214,terbutaline,We studied the effects of terbutaline on microglial activation in different brain regions and behavioral outcomes in developing rats.,17400887_4,0
9217,terbutaline,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,0
9222,terbutaline,"Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex, as well as in cerebellar and cerebrocortical white matter.",17400887_6,0
9228,terbutaline,None of these effects occurred in animals given terbutaline on PN 11 to 14.,17400887_7,0
9232,terbutaline,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,0
9345,dex,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,0
9354,Dex,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,0
9369,methylprednisolone,Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space.,17466854_0,0
9372,methylprednisolone,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,0
9381,lignocaine,METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain lignocaine.,17466854_3,0
9384,methylprednisolone,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0
9393,methylprednisolone,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,0
9432,locomotor hyperactivity,Amphetamine-induced locomotor hyperactivity was similar in all groups.,17490864_6,1
9456,dobutamine,Simultaneous measurements of ECG and brachial artery dP/dtejc were performed at each dobutamine level.,17491223_4,0
9459,dobutamine,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,0
9473,acute myocardial infarction,Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.,1749407_1,1
9475,acute myocardial infarction,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,1
9492,thrombotic,"Finally, the contribution of a primary, thrombotic effect of cocaine has not been excluded.",1749407_9,1
9514,bromocriptine,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,0
9537,iopamidol,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,0
9539,iodixanol,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,0
9542,iopamidol,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,0
9543,iodixanol,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,0
9548,creatinine,Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications.,17562951_3,0
9567,iopamidol,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0
9568,iodixanol,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0
9571,iopamidol,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0
9572,iodixanol,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0
9575,iopamidol,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,0
9577,iopamidol,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0
9578,iodixanol,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0
9584,liver disease,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,1
9588,cardiac arrest,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,1
9599,liver damage,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,1
9603,maltolyl p-coumarate,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,0
9604,cognitive deficits,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,1
9610,maltolyl p-coumarate,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,0
9614,maltolyl p-coumarate,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,0
9618,Maltolyl p-coumarate,Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,17600377_3,0
9619,cognitive deficits,Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,17600377_3,1
9623,maltolyl p-coumarate,We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.,17600377_4,0
9626,maltolyl p-coumarate,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,0
9629,maltolyl p-coumarate,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,0
9635,maltolyl p-coumarate,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,0
9639,lipopolysaccharide,Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.,17608141_0,0
9644,lipopolysaccharide,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,0
9649,Lipopolysaccharide,Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.,17608141_3,0
9652,lipopolysaccharide,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,0
9655,lipopolysaccharide,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,0
9657,lipopolysaccharide,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0
9661,lipopolysaccharide,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0
9663,lipopolysaccharide,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,0
9677,rhabdomyolysis,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,1
9682,rhabdomyolysis,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,1
9691,blood urea nitrogen,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0
9692,creatinine,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0
9693,aspartate,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0
9700,creatinine,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,0
9702,rhabdomyolysis,DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.,17615423_7,1
9713,levofloxacin,Interaction between warfarin and levofloxacin: case series.,17639754_0,0
9717,Levofloxacin,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,0
9723,levofloxacin,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0
9725,levofloxacin,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0
9726,levofloxacin,We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.,17639754_4,0
9727,levofloxacin,Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.,17639754_5,0
9728,leukoencephalopathy,Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.,17682013_0,1
9730,leukoencephalopathy,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,1
9744,leukoencephalopathy,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,1
9747,5-fluorouracil,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0
9749,capecitabine,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0
9762,leukoencephalopathy,CONCLUSIONS: Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed.,17682013_11,1
9770,pulmonary hypertension,Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.,17702969_0,1
9773,pulmonary hypertension,Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.,17702969_2,1
9774,pulmonary hypertension,"The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents.",17702969_3,1
9781,pulmonary hypertension,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,1
9797,pulmonary hypertension,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,1
9801,peripheral neuropathy,Disulfiram-induced transient optic and peripheral neuropathy: a case report.,17786501_0,1
9803,peripheral neuropathy,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,1
9908,17beta-estradiol,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,0
9930,telithromycin,Acute hepatitis attack after exposure to telithromycin.,17919553_0,0
9931,hepatotoxicity,INTRODUCTION: Antibiotic-associated hepatotoxicity is rare.,17919553_1,1
9933,hepatic injury,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,1
9938,telithromycin,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,0
9942,aspartate,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0
9947,telithromycin,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,0
9948,Telithromycin,DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use.,17919553_9,0
9954,telithromycin,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,0
9955,telithromycin,Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.,17919553_12,0
9957,telithromycin,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,0
10005,Dilated cardiomyopathy,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,1
10042,rheumatoid arthritis,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,1
10050,diclofenac,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,0
10051,rheumatoid arthritis,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,1
10053,diclofenac,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,0
10063,diclofenac,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,0
10066,diclofenac,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,0
10072,diclofenac,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,0
10074,diclofenac,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,0
10079,diclofenac,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,0
10094,ciprofloxacin-,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,0
10095,ciprofloxacin-,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,0
10101,Acute liver failure,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,1
10102,paracetamol,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,0
10104,hepatotoxicity,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,1
10107,paracetamol,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,0
10111,paracetamol,A paracetamol serum level obtained in one of these patients was not in the toxic range.,18004067_3,0
10114,hepatotoxicity,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,1
10117,paracetamol,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,0
10121,paracetamol,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0
10124,paracetamol,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0
10125,propofol,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,0
10127,propofol,BACKGROUND: Pain on injection of propofol is unpleasant.,18006530_1,0
10128,propofol,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0
10130,propofol,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0
10144,propofol,"After the target Ce was achieved, the infusion of propofol was started.",18006530_5,0
10147,propofol,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0
10148,propofol,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0
10159,propofol,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0
10161,propofol,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0
10214,peripheral neuropathy,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,1
10226,polyneuropathy,A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy.,18023325_8,1
10236,polyneuropathy,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,1
10238,levetiracetam,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,0
10240,levetiracetam,BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.,18081909_1,0
10241,idiopathic epilepsy,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,1
10271,propranolol,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0
10277,yohimbine,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0
10332,Hyperprolactinemia,Hyperprolactinemia can reduce fertility and libido.,18162529_1,1
10334,hyperprolactinemia,We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.,18162529_3,1
10339,hyperprolactinemia,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,1
10340,sulpiride,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,0
10343,Sulpiride,Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.,18162529_5,0
10357,sulpiride,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,0
10358,Sulpiride,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0
10370,hyperprolactinemia,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,1
10407,Tacrolimus,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,0
10411,metabolic acidosis,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,1
10413,tacrolimus,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0
10414,sirolimus,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0
10421,mitochondrial dysfunction,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,1
10422,tacrolimus,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,0
10499,thrombotic,"Similarly, thrombotic risk increased with age and OD values.",18208574_10,1
10518,myelosuppression,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,1
10520,thromboembolic,Of concern was the occurrence of four thromboembolic events.,18217897_7,1
10535,hyperalgesia,"To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.",18221780_3,1
10557,trihexyphenidyl,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,0
10560,trihexyphenidyl,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,0
10570,trihexyphenidyl,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,0
10578,trihexyphenidyl,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,0
10583,trihexyphenidyl,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,0
10593,trihexyphenidyl,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,0
10597,renal dysfunction,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,1
10607,cyclosporine,"In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS.",18261172_4,0
10623,renal dysfunction,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,1
10679,hexamethonium,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0
10706,thromboembolic,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,1
10735,Amikacin,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0
10736,aminoglycoside,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0
10741,nephrotoxicity,"To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.",18356633_3,1
10747,aminoglycoside,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0
10749,amikacin,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0
10750,nephrotoxicity,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,1
10751,creatinine,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,0
10752,amikacin,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,0
10753,nephrotoxicity,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,1
10758,nephrotoxicity,"The occurrence of nephrotoxicity was similar between the two dosing regimens, but the distribution of risk factors was variable between the two groups.",18356633_8,1
10800,Hepatotoxicity,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,1
10802,sulfasalazine,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,0
10817,hepatotoxicity,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,1
10818,sulfasalazine,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,0
10822,hepatotoxicity,The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.,18405372_6,1
10823,sulfasalazine,The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.,18405372_6,0
10826,interstitial nephritis,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,1
10832,hepatotoxicity,Drug-related hepatotoxicity was judged probable or highly probable in 8 patients.,18405372_13,1
10833,hepatotoxicity,The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.,18405372_14,1
10834,sulfasalazine,The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.,18405372_14,0
10835,hepatotoxicity,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,1
10837,sulfasalazine,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,0
10840,neurotoxicity,Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.,18410508_0,1
10851,neurotoxicity,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,1
10854,neurotoxicity,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,1
10860,neurotoxicity,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,1
10904,amino acid,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,0
10907,amino acid,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0
10908,aspartate,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0
10922,aspartate,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,0
10927,aspartate,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,0
10930,aspartate,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,0
10933,amino acid,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0
10934,aspartate,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0
10938,aspartate,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,0
10986,liver disease,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,1
11008,cyclophosphamide,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,0
11015,cyclophosphamide,VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.,18483878_2,0
11075,terbutaline,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,0
11076,terbutaline,"Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2.",1848636_7,0
11078,terbutaline,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0
11084,terbutaline,"In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%).",1848636_9,0
11091,everolimus,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,0
11097,Neurotoxicity,Neurotoxicity is a potentially serious toxic effect.,18503483_2,1
11107,methylprednisolone,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,0
11109,everolimus,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,0
11159,renal dysfunction,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,1
11161,renal damage,"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.",18541230_5,1
11177,sevoflurane,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,0
11179,sevoflurane,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,0
11183,sevoflurane,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,0
11196,sevoflurane,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,0
11198,Valvular heart disease,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,1
11201,pergolide,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,0
11206,pergolide,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,0
11213,pergolide,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,0
11217,pergolide,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,0
11221,mitral regurgitation,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,1
11225,pergolide,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,0
11226,pergolide,Severity of regurgitation was not correlated with pergolide cumulative dose.,18560792_11,0
11228,pergolide,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,0
11230,Pergolide,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,0
11231,valvular heart disease,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,1
11237,pergolide,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,0
11262,platelet aggregation,The heparin-induced platelet aggregation test was negative in these patients.,18589141_12,1
11271,adriamycin,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,0
11274,adriamycin,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,0
11277,3-methyladenine,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,0
11281,adriamycin,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,0
11306,adriamycin,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,0
11314,adriamycin,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,0
11317,adriamycin,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,0
11324,cardiotoxic,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,1
11332,cardiac dysfunction,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,1
11344,cardiac dysfunction,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,1
11359,rapamycin,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0
11360,sirolimus,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0
11364,sirolimus,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0
11367,sirolimus,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0
11368,sirolimus,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0
11418,cardiotoxicity,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,1
11419,Adriamycin,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,0
11421,cardiotoxicity,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,1
11424,cardiotoxicity,"Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin-induced cardiotoxicity.",18674790_2,1
11434,cardiotoxicity,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,1
11436,cardiotoxicity,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,1
11437,cardiac dysfunction,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,1
11460,cardiotoxicity,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,1
11488,vasospasm,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,1
11495,vasospasm,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,1
11497,vasospasm,Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.,18726058_5,1
11508,sensorineural hearing loss,One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss.,18726058_12,1
11511,vasospasm,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,1
11530,fulminant hepatic failure,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,1
11535,hepatotoxicity,The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.,18752389_4,1
11539,hepatotoxicity,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,1
11552,hepatotoxicity,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,1
11556,hepatotoxicity,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,1
11559,hepatotoxicity,Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.,18752389_13,1
11574,creatinine,"Urinary volume and serum creatinine levels recovered to the normal range, with urinary protein disappearing completely within 40 days.",18754075_4,0
11599,nephrotic,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,1
11647,myocardial injury,Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.,18808529_0,1
11648,myocardial damage,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,1
11684,Alpha-lipoic acid,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,0
11686,neurotoxicity,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,1
11689,neurotoxicity,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,1
11693,alpha-lipoic acid,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0
11695,peripheral neuropathy,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,1
11701,paclitaxel,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0
11702,cisplatin,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0
11704,alpha-lipoic acid,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,0
11709,alpha-lipoic acid,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,0
11710,cisplatin,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0
11711,paclitaxel,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0
11714,Alpha-lipoic acid,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0
11716,neurotoxicity,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,1
11723,paclitaxel,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0
11724,cisplatin,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0
11725,neurotoxicity,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,1
11726,Alpha-lipoic acid,"Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.",18809400_7,0
11731,alpha-lipoic acid,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,0
11770,oral contraceptives,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,0
11773,Oral Contraceptives,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,0
11799,dystonia,The major effect was on dystonia subscore.,18951540_5,1
11810,Ifosfamide,Ifosfamide continuous infusion without mesna.,1899352_0,0
11811,mesna,Ifosfamide continuous infusion without mesna.,1899352_0,0
11813,ifosfamide,Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna.,1899352_2,0
11814,Mesna,Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna.,1899352_2,0
11816,ifosfamide,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0
11818,Mesna,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0
11829,Mesna,"The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.",1899352_10,0
11832,ifosfamide,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0
11833,Mesna,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0
11848,ventricular tachycardia,A case of ventricular tachycardia related to caffeine pretreatment.,18997632_0,1
11856,ventricular tachycardia,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,1
11857,ventricular arrhythmias,"Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias.",18997632_4,1
11883,green tea,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,0
11887,green tea,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0
11907,green tea,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
11918,green tea,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
11921,green tea,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,0
11935,bupropion,Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.,19105845_0,0
11937,bupropion,"This is important, since different controlled release formulations of bupropion release the active drug at different rates.",19105845_2,0
11959,bupropion,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,0
11962,everolimus,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0
11963,tacrolimus,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0
11974,Everolimus,"Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.",19135948_2,0
11975,sirolimus,"Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.",19135948_2,0
11977,everolimus,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0
11978,tacrolimus,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0
11985,mucositis,"All patients engrafted, and only 1 patient experienced grade IV mucositis.",19135948_4,1
12025,ototoxicity,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,1
12033,Renal papillary necrosis,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,1
12035,paracetamol,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,0
12055,sulphasalazine,Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.,19203554_0,0
12060,sulphasalazine,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,0
12069,sulphasalazine,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,0
12079,sulphasalazine,This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.,19203554_7,0
12099,renal injury,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,1
12111,glomerular sclerosis,"HS diet for 4 wk caused a progressive increase in BP, protein and albumin excretion, and glomerular sclerosis in male DS rats, which were attenuated by castration.",19211690_9,1
12113,renal injury,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,1
12117,renal injury,Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.,19211690_11,1
12151,parkinsonian,There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months.,19234905_6,1
12184,cyclophosphamide,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,0
12189,cyclophosphamide,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,0
12198,cyclophosphamide,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,0
12200,cyclophosphamide,The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2).,19274460_3,0
12207,cyclophosphamide,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,0
12257,Cardiotoxicity,Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.,19300240_2,1
12267,akinetic,Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.,19300240_7,1
12278,Bradykinin,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0
12280,streptozotocin,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0
12281,hyperalgesia,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,1
12293,bradykinin,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
12297,bradykinin,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,0
12309,bradykinin,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0
12310,hyperalgesia,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,1
12319,hyperalgesia,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,1
12322,bradykinin,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,0
12327,neuropathic pain,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,1
12411,sirolimus,Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.,19356053_0,0
12413,Sirolimus,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,0
12415,nephrotoxicity,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,1
12419,sirolimus,To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus.,19356053_2,0
12421,sirolimus,We have encountered several patients who developed substantial proteinuria associated with sirolimus use.,19356053_3,0
12422,sirolimus,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,0
12423,sirolimus,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,0
12426,sirolimus,METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.,19356053_5,0
12431,creatinine,"In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.",19356053_6,0
12434,sirolimus,"Laboratory results were compared between prior, during and following sirolimus use.",19356053_7,0
12436,sirolimus,In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.,19356053_10,0
12437,sirolimus,Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.,19356053_11,0
12439,sirolimus,"In most patients, discontinuation of sirolimus resulted in a decrease, but not resolution, of proteinuria.",19356053_12,0
12440,Sirolimus,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,0
12442,sirolimus,"Proteinuria may improve, but does not resolve, when sirolimus is withdrawn.",19356053_14,0
12473,gallbladder disease,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,1
12493,breast cancer,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,1
12494,gallbladder disease,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,1
12497,gallbladder disease,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,1
12498,breast cancer,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,1
12522,secondary hyperalgesia,Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.,19387625_0,1
12523,secondary hyperalgesia,"However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.",19387625_2,1
12524,secondary hyperalgesia,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,1
12529,secondary hyperalgesia,"Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.",19387625_4,1
12533,secondary hyperalgesia,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,1
12538,salvianolic acid,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,0
12549,aspartate,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0
12551,malondialdehyde,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0
12565,cardiac dysfunction,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,1
12566,myocardial injury,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,1
12570,myocardial damage,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,1
12576,neurotoxicity,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,1
12577,paclitaxel,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,0
12578,peripheral neuropathy,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,1
12580,paclitaxel,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,0
12581,amino acid,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,0
12585,peripheral neuropathy,"This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.",19473225_2,1
12588,ovarian cancer,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,1
12595,neurotoxicity,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,1
12600,neurotoxicity,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,1
12706,Sulpiride,Sulpiride is a selective D2-receptor antagonist with antipsychotic and antidepressant properties.,1967484_1,0
12711,dystonia,We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.,1967484_3,1
12712,sulpiride,We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.,1967484_3,0
12761,sodium nitroprusside,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,0
12769,sodium nitroprusside,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,0
12774,Sodium nitroprusside,Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.,1969772_8,0
12782,levofloxacin,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,0
12785,levofloxacin,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,0
12791,levofloxacin,The main search terms utilized were case report and levofloxacin.,19707748_3,0
12794,levofloxacin,Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.,19707748_6,0
12796,levofloxacin,CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.,19707748_7,0
12804,dextran,A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.,19719056_2,0
12810,dextran,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,0
12842,ventricular tachycardia,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,1
12847,ouabain,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,0
12855,ouabain,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,0
12860,oxycodone,Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.,19729346_0,0
12864,oxycodone,"This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.",19729346_1,0
12867,oxycodone,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,0
12868,oxycodone,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,0
12885,oxycodone,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,0
12889,oxycodone,"PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults.",19729346_7,0
12927,olanzapine,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0
12970,neuronal damage,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,1
12984,neuronal damage,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,1
13003,neuronal damage,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,1
13013,suxamethonium,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,0
13015,cardiac toxicity,Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.,19820426_0,1
13019,dilated cardiomyopathy,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,1
13042,creatinine,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,0
13050,creatinine,"The dosing schedule, duration of lithium treatment, and daily dose of lithium did not affect maximum osmolality or creatinine clearance.",1987816_5,0
13174,creatinine,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0
13190,tacrolimus,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,0
13193,Tacrolimus,Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation.,19917396_1,0
13196,cardiac toxicity,"However, adverse effects include cardiac toxicity.",19917396_2,1
13197,tacrolimus,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,0
13203,tacrolimus,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0
13204,tacrolimus,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0
13205,tacrolimus,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,0
13207,tacrolimus,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,0
13208,tacrolimus,"In patients receiving tacrolimus therapy, blood concentration should be carefully controlled and extreme attention paid to cardiac involvement.",19917396_9,0
13210,Nimodipine,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.,19923525_0,0
13211,memory impairment,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.,19923525_0,1
13214,nimodipine,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,0
13274,Hemolytic anemia,Hemolytic anemia associated with the use of omeprazole.,1992636_0,1
13283,hemolytic anemia,We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.,1992636_4,1
13287,hemolytic anemia,"The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.",1992636_8,1
13312,6-hydroxydopamine,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,0
13313,akinetic,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,1
13333,acute myocardial infarction,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,1
13336,sorafenib,"Two weeks before his admission, sorafenib had been started.",19944333_2,0
13342,sorafenib,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,0
13344,sorafenib,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,0
13348,Sorafenib,Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival.,19944333_10,0
13356,sorafenib,Our report may show an adverse effect on the Rho/ROCK pathway by sorafenib use.,19944333_12,0
13401,propofol,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,0
13453,argatroban,Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.,20003049_0,0
13461,argatroban,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,0
13470,argatroban,STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time (ECT) assay.,20003049_4,0
13472,argatroban,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,0
13473,argatroban,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,0
13477,argatroban,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,0
13480,argatroban,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,0
13482,coagulopathy,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,1
13487,argatroban,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,0
13489,coagulopathy,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,1
13491,cardiac arrhythmias,Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.,2004_0,1
13496,ventricular tachycardia,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,1
13501,ventricular arrhythmias,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,1
13505,propranolol,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,0
13509,cardiac arrhythmias,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,1
13515,azidothymidine,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,0
13558,propofol,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,0
13569,propofol,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,0
13574,bupropion,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,0
13575,sexual dysfunction,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,1
13578,bupropion,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,0
13579,sexual dysfunction,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,1
13583,bupropion,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,0
13595,bupropion,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,0
13597,bupropion,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,0
13601,bupropion,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,0
13602,bupropion,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,0
13608,Bupropion,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,0
13609,bupropion,These results provide empirical support for conducting a further study of bupropion.,20067456_13,0
13634,modafinil,Normalizing effects of modafinil on sleep in chronic cocaine users.,20080983_0,0
13635,modafinil,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,0
13638,modafinil,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,0
13646,modafinil,"Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.",20080983_7,0
13650,modafinil,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,0
13660,modafinil,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,0
13662,Modafinil,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,0
13667,modafinil,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,0
13689,mitral regurgitation,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,1
13708,variant angina,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,1
13711,variant angina,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,1
13716,variant angina,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,1
13717,coronary spasm,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,1
13730,variant angina,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,1
13735,meth mouth,"Oral manifestations of ""meth mouth"": a case report.",20098969_0,1
13738,meth mouth,"AIM: The aim of the documentation of this clinical case is to make clinicians aware of ""meth mouth"" and the medical risks associated with this serious condition.",20098969_1,1
13747,meth mouth,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,1
13758,meth mouth,"SUMMARY: The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of ""meth mouth."" Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.",20098969_8,1
13764,meth mouth,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,1
13768,diabetic nephropathy,The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.,20103708_0,1
13769,Diabetic nephropathy,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,1
13776,diabetic nephropathy,"Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy.",20103708_3,1
13780,diabetic nephropathy,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,1
13782,diabetic nephropathy,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,1
13783,diabetic nephropathy,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,1
13787,diabetic nephropathy,RESULTS: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels.,20103708_5,1
13792,renal damage,"In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced renal damage.",20103708_6,1
13795,renal injury,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,1
13801,diabetic nephropathy,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,1
13818,diabetic nephropathy,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,1
13821,diabetic nephropathy,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,1
13870,creatinine,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,0
13876,renal damage,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,1
13882,renal injury,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,1
13884,renal injury,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,1
13895,acute liver failure,"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.",20196116_0,1
13897,acute liver failure,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,1
13975,risperidone,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,0
13978,hyperprolactinemia,OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.,20331935_1,1
13983,risperidone,"METHOD: Medically healthy 7- to 17-year-old males chronically treated, in a naturalistic setting, with risperidone were recruited for this cross-sectional study through child psychiatry outpatient clinics between November 2005 and June 2007.",20331935_2,0
13997,Hyperprolactinemia,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,1
13999,risperidone,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,0
14001,hyperprolactinemia,Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.,20331935_7,1
14017,risperidone,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,0
14018,hyperprolactinemia,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,1
14019,hyperprolactinemia,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,1
14039,yohimbine,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0
14046,yohimbine,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,0
14047,yohimbine,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,0
14053,tacrolimus,Rosaceiform dermatitis associated with topical tacrolimus treatment.,20466178_0,0
14054,tacrolimus,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,0
14061,tacrolimus,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,0
14065,acute lymphoblastic leukemia,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,1
14067,acute lymphoblastic leukemia,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,1
14074,peripheral neuropathy,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,1
14078,leukoencephalopathy,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,1
14079,temporal lobe epilepsy,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,1
14122,cisplatin,injection of cisplatin (5 mg/kg).,20510337_2,0
14124,cisplatin,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,0
14126,blood urea nitrogen,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0
14127,creatinine,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0
14128,cisplatin,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0
14131,glutathione,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
14138,cisplatin,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
14141,cisplatin,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,0
14159,liver disease,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,1
14166,asenapine,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.,20520283_0,0
14169,Asenapine,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,0
14174,asenapine,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,0
14175,asenapine,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,0
14177,asenapine,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0
14180,asenapine,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0
14183,asenapine,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,0
14190,asenapine,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,0
14192,Extrapyramidal symptoms,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,1
14194,asenapine,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,0
14199,asenapine,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,0
14201,extrapyramidal symptoms,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,1
14203,nelarabine,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0
14204,etoposide,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0
14205,cyclophosphamide,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0
14208,nelarabine,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0
14210,etoposide,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0
14212,cyclophosphamide,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0
14229,etoposide,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,0
14230,cyclophosphamide,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,0
14231,neurotoxicity,Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.,20533999_0,1
14246,adriamycin,Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.,2054792_0,0
14266,salbutamol,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,0
14271,salbutamol,The patient noticed that before these episodes he had been using an inhalator of salbutamol.,20552622_4,0
14283,Salbutamol,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,0
14287,salbutamol,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,0
14328,amino acid,"Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing, escape-like behavior, and immobility.",20558148_2,0
14397,memory impairment,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,1
14465,Suxamethonium,Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.,20633755_0,0
14467,Suxamethonium,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,0
14494,Curcumin,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,0
14497,carbamazepine,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,0
14499,carbamazepine,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,0
14505,Curcumin,"Curcumin has shown antioxidant, anti-inflammatory and neuro-protective properties.",20667451_3,0
14507,curcumin,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,0
14508,phenobarbitone-,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,0
14512,curcumin,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0
14513,carbamazepine,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0
14518,carbamazepine,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0
14519,malondialdehyde,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0
14520,glutathione,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0
14521,carbamazepine,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,0
14523,curcumin,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,0
14527,Curcumin,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0
14529,carbamazepine,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0
14530,curcumin,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0
14534,carbamazepine,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0
14535,curcumin,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,0
14536,carbamazepine,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,0
14578,memory impairment,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,1
14582,cognitive deficits,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,1
14589,sorafenib,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0
14613,olanzapine,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0
14653,memory impairment,The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.,2071257_1,1
14658,capecitabine,Safety of capecitabine: a review.,20722491_0,0
14660,5-fluorouracil,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,0
14662,capecitabine,AREAS COVERED IN THIS REVIEW: This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety.,20722491_2,0
14663,capecitabine,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,0
14667,capecitabine,We also explore different dosing and schedules of capecitabine administration.,20722491_4,0
14668,Capecitabine,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,0
14675,capecitabine,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,0
14676,hand-foot syndrome,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,1
14677,Capecitabine,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,0
14712,acute liver failure,Long-term prognosis for transplant-free survivors of paracetamol-induced acute liver failure.,20735774_0,1
14714,acute liver failure,BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown.,20735774_1,1
14715,acute liver failure,AIM: To examine whether paracetamol-induced acute liver failure increases long-term mortality.,20735774_2,1
14717,liver injury,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,1
14722,liver injury,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,1
14723,acute liver failure,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,1
14725,liver injury,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,1
14726,acute liver failure,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,1
14729,acute liver failure,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,1
14730,liver disease,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,1
14731,acute liver failure,These observations speak against long-term effects of acute liver failure.,20735774_7,1
14734,acute liver failure,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,1
14735,acute liver failure,CONCLUSIONS: Paracetamol-induced acute liver failure did not affect long-term mortality.,20735774_9,1
14758,neurotensin,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,0
14765,neurotensin,"Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum, and systemic administration of a neurotensin analog could produce antiparkinsonian effects.",20882060_2,0
14768,neurotensin,The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.,20882060_3,0
14771,neurotensin,RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.,20882060_5,0
14776,neurotensin,Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration.,20882060_6,0
14778,neurotensin,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0
14781,neurotensin,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0
14782,neurotensin,CONCLUSION: Activation of pallidal neurotensin receptors may be involved in neurotensin-induced antiparkinsonian effects.,20882060_8,0
14788,leukoencephalopathy,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,1
14798,leukoencephalopathy,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,1
14820,6-hydroxydopamine,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,0
14902,renal toxicity,"Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.",21418164_6,1
14907,Perhexiline maleate,Perhexiline maleate and peripheral neuropathy.,220563_0,0
14908,peripheral neuropathy,Perhexiline maleate and peripheral neuropathy.,220563_0,1
14909,Peripheral neuropathy,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,1
14910,perhexiline maleate,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,0
14927,4'-0-tetrahydropyranyladriamycin,A phase I study of 4'-0-tetrahydropyranyladriamycin.,2224762_0,0
14930,4'-0-tetrahydropyranyladriamycin,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,0
14945,mucositis,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,1
14946,Myelosuppression,Myelosuppression was more in patients with hepatic dysfunction.,2224762_9,1
14970,desferrioxamine,Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.,2234245_0,0
14973,desferrioxamine,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,0
14985,Desferrioxamine,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,0
14989,desferrioxamine,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,0
14992,desferrioxamine,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,0
15001,azidothymidine,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,0
15028,chronic renal failure,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,1
15034,mazindol,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,0
15039,mazindol,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,0
15045,mazindol,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,0
15046,Mazindol,Mazindol did not benefit strength at any point in the study.,2266990_5,0
15048,mazindol,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0
15050,dry mouth,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,1
15053,mazindol,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0
15054,mazindol,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0
15058,mazindol,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0
15063,Mazindol,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,0
15068,cycloheximide,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0
15076,cycloheximide,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,0
15085,alpha-methyldopa,The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.,227508_2,0
15097,alpha-methyldopa,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,0
15100,Neurotoxicity,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,1
15110,peripheral neuropathy,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,1
15112,peripheral neuropathy,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,1
15117,stress incontinence,Prazosin-induced stress incontinence.,2304736_0,1
15118,stress incontinence,"A case of genuine stress incontinence due to prazosin, a common antihypertensive drug, is presented.",2304736_1,1
15130,stress incontinence,"Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.",2304736_7,1
15139,coronary spasm,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,1
15145,ifosfamide,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,0
15146,breast cancer,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,1
15148,breast cancer,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,1
15150,cisplatin,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0
15152,ifosfamide,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0
15158,Ifosfamide,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,0
15160,ifosfamide,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0
15161,cisplatin,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0
15163,ifosfamide,We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.,2320800_7,0
15189,hyperalgesia,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,1
15195,hyperalgesia,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,1
15224,apnoea,The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i.v.,2334618_2,1
15225,bupivacaine,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,0
15233,apnoea,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,1
15258,Cardiac arrhythmias,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,1
15281,ventricular arrhythmias,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,1
15293,dipyridamole,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,0
15297,Dipyridamole,Dipyridamole significantly increased coronary blood flow before and after 7.5 or 15 mm/kg i.v.,2348231_6,0
15303,cerebral haemorrhage,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,1
15304,cerebral haemorrhage,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,1
15309,Cerebral haemorrhage,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,1
15312,cerebral haemorrhage,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,1
15314,parkinsonian,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,1
15342,hepatocellular carcinoma,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,1
15387,ventricular arrhythmias,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,1
15390,ventricular arrhythmias,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,1
15421,picrotoxin,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
15425,bicuculline,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
15436,picrotoxin,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,0
15468,cardiac toxicity,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,1
15512,amantadine,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,0
15514,amantadine,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,0
15521,Amantadine,Amantadine treatment produced a biphasic effect on mouse motility.,2484011_3,0
15527,amantadine,Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive.,2484011_5,0
15532,amantadine,"The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment.",2484011_6,0
15534,amantadine,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,0
15538,amantadine,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,0
15544,amantadine,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,0
15547,amantadine,The results suggest a strain-dependent effect of amantadine on motility and indicate a differential response to the acute and multiple dose regimens used.,2484011_10,0
15551,amantadine,The BALB/C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine.,2484011_11,0
15558,amantadine,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0
15562,cyclophosphamide,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,0
15563,ifosfamide,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,0
15575,mesna,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,0
15587,carbamazepine,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,0
15590,carbamazepine,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,0
15594,carbamazepine,This is the first report of such an unusual reaction to carbamazepine.,2522601_2,0
15597,Azidothymidine,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,0
15655,major depression,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,1
15665,propranolol,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,0
15684,hyperalgesia,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,1
15689,hyperalgesia,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,1
15705,adriamycin,"Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.",2559236_2,0
15725,renal injury,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,1
15739,glomerular sclerosis,Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats.(ABSTRACT TRUNCATED AT 250 WORDS),2559236_10,1
15780,alfentanil,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,0
15795,alfentanil,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,0
15809,akinetic,"The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)",2569282_11,1
15818,hepatotoxicity,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,1
15839,citalopram,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0
15840,5-azacytidine,5-azacytidine potentiates initiation induced by carcinogens in rat liver.,2578334_0,0
15843,5-azacytidine,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,0
15854,2-acetylaminofluorene,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,0
15879,bupivacaine,"Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).",2594614_1,0
15886,bupivacaine,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0
15889,bupivacaine,injection of bupivacaine were ineffective.,2594614_4,0
15891,bupivacaine,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,0
15946,methyl dopa,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,0
15953,phenylacetic acid,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,0
15956,diclofenac,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,0
15958,ketoconazole,Arterial hypertension as a complication of prolonged ketoconazole treatment.,2632720_0,0
15960,ketoconazole,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,0
15961,ketoconazole,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,0
15965,11-deoxycortisol,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,0
15967,11-deoxycortisol,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,0
15969,ketoconazole,Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.,2632720_5,0
15982,Renal damage,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,1
15988,bradykinin,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,0
16005,nitroprusside,A randomized comparison of labetalol and nitroprusside for induced hypotension.,2696505_0,0
16013,Nitroprusside,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0
16017,nitroprusside,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0
16020,nitroprusside,It was concluded that labetalol offers advantages over nitroprusside.,2696505_6,0
16039,renal dysfunction,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,1
16043,tubular necrosis,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,1
16050,tubular necrosis,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,1
16057,tubular necrosis,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,1
16126,carbamazepine,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,0
16128,carbamazepine,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,0
16133,lidocaine-,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,0
16142,lidocaine-,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,0
16158,creatinine,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,0
16160,creatinine,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0
16162,creatinine,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0
16176,creatinine,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,0
16190,oral contraceptive,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,0
16205,terbutaline,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,0
16208,terbutaline,"In the 7-hour period after terbutaline administration, plasma samples were taken for determination of plasma potassium levels and drug concentrations.",2826064_4,0
16212,terbutaline,The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects.,2826064_5,0
16214,terbutaline,"Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.",2826064_6,0
16215,terbutaline,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,0
16242,Flestolol,Flestolol: an ultra-short-acting beta-adrenergic blocking agent.,2870085_0,0
16244,Flestolol,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,0
16249,Flestolol,Flestolol is metabolized by plasma esterases and has an elimination half-life of approximately 6.5 minutes.,2870085_2,0
16253,flestolol,"In long-term infusion studies, flestolol was well tolerated at the effective beta-blocking dose (5 micrograms/kg/min) for up to seven days.",2870085_4,0
16255,Flestolol,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,0
16258,flestolol,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,0
16260,Flestolol,Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.,2870085_6,0
16264,flestolol,Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers.,2870085_7,0
16268,Flestolol,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,0
16272,flestolol,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,0
16274,flestolol,"It is concluded that flestolol is a potent, well-tolerated, ultra-short-acting beta-adrenergic blocking agent.",2870085_11,0
16277,flestolol,Use of flestolol in the critical care setting is currently undergoing investigation.,2870085_12,0
16295,Propranolol,Propranolol had no effect on stimulus-induced overflow in either group.,2886572_7,0
16309,bromocriptine,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,0
16311,bromocriptine,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,0
16312,prolactinoma,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,1
16318,prolactinoma,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,1
16319,bromocriptine,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,0
16326,prolactinoma,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,1
16333,bromocriptine,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,0
16337,prolactinoma,"The prolactinoma cells at this time were well granulated, with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae.",2887062_7,1
16346,prolactinoma,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,1
16349,bromocriptine,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,0
16355,bromocriptine,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,0
16366,aspartate,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,0
16392,picrotoxin,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,0
16408,sulfasalazine,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,0
16410,sulfasalazine,"After cessation of the sulfasalazine and completion of a six-week course of corticosteroids, these problems resolved over a period of four to six months.",2894766_2,0
16416,sulfasalazine,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,0
16463,carbamazepine,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,0
16465,Carbamazepine,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,0
16488,dipyridamole,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,0
16491,dipyridamole,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,0
16551,hypothyroid,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,1
16552,hypothyroid,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,1
16590,6-hydroxydopamine,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0
16691,rheumatoid arthritis,Toxicity due to remission inducing drugs in rheumatoid arthritis.,3084782_0,1
16693,rheumatoid arthritis,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,1
16725,ketoconazole,Hepatic reactions associated with ketoconazole in the United Kingdom.,3101906_0,0
16727,Ketoconazole,Ketoconazole was introduced in the United Kingdom in 1981.,3101906_1,0
16729,hepatotoxicity,"By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug, including five deaths.",3101906_2,1
16731,hepatotoxicity,"The mean age of patients in the 16 probable cases was 57.9, with hepatotoxicity being more common in women.",3101906_5,1
16739,ketoconazole,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,0
16743,ketoconazole,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,0
16744,hepatic injury,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,1
16746,hepatotoxicity,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,1
16748,hepatotoxicity,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,1
16758,hemolytic uremic syndrome,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,1
16760,Hemolytic Uremic Syndrome,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,1
16787,alfentanil,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,0
16797,alfentanil,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,0
16799,alfentanil,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0
16800,alfentanil,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0
16802,alfentanil,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,0
16836,oral contraceptives,Three patients developed chorea while receiving oral contraceptives.,3123611_1,0
16850,alfentanil,"Following instrumentation, halothane was discontinued and alfentanil (125 mu/kg) administered iv during emergence from halothane anesthesia.",3125768_4,0
16859,alfentanil,"In five rats that did not become rigid, ICP and CVP did not change following alfentanil.",3125768_7,0
16860,alfentanil,"These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.",3125768_8,0
16891,cardiotoxicity,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,1
16894,cardiotoxic,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,1
16909,cardiotoxicity,"None of the other patients developed clinical cardiotoxicity, nor did the studied parameters change.",3137399_8,1
16911,cardiotoxicity,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,1
16944,cis-platin,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,0
16945,5-fluorouracil,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,0
16947,cis-platin,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,0
16957,cardiotoxicity,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,1
16960,cardiotoxicity,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,1
16977,Etoposide,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0
16978,Cyclophosphamide,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0
16980,Cisplatin,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0
16981,Etoposide,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0
16982,Cyclophosphamide,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0
16998,locomotor hyperactivity,Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.,3220106_0,1
17023,locomotor hyperactivity,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,1
17031,sodium nitroprusside,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,0
17033,nitroprusside,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,0
17043,nitroprusside,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,0
17048,Nitroprusside,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,0
17056,nitroprusside,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,0
17063,nitroprusside,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,0
17067,nitroprusside,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,0
17082,vasospasm,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,1
17096,cyclosporine,"In group I, cyclosporine was given before the procedure at a loading dose of 17.5 mg/kg and then continued after the procedure to keep a whole blood level about 1000 ng/ml.",3311455_2,0
17099,cyclosporine,"In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week.",3311455_3,0
17103,blood urea nitrogen,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,0
17104,creatinine,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,0
17106,nephrotoxicity,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,1
17107,cyclosporine,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,0
17110,creatinine,"Despite this improvement in late renal function, group II still shows a slow rise in serum creatinine.",3311455_6,0
17111,cyclosporine,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,0
17112,nephrotoxicity,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,1
17122,sodium nitroprusside,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,0
17158,carbamazepine,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0
17159,carbamazepine,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0
17160,carbamazepine,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0
17166,fluphenazine enanthate,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,0
17179,metabolic acidosis,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,1
17181,metabolic acidosis,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,1
17184,paracetamol,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,0
17187,Sexual dysfunction,Sexual dysfunction among patients with arthritis.,3409645_0,1
17188,sexual dysfunction,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,1
17189,rheumatoid arthritis,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,1
17205,sexual dysfunction,"Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with sexual dysfunction, sexual dissatisfaction and being female.",3409645_6,1
17213,paracetamol,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0
17215,renal papillary necrosis,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,1
17218,paracetamol,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0
17219,renal papillary necrosis,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,1
17221,paracetamol,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,0
17222,renal papillary necrosis,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,1
17239,hemolytic anemia,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,1
17244,hemolytic anemia,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,1
17248,glutathione,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,0
17261,hemolytic anemia,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,1
17290,breast cancer,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,1
17291,ovarian cancer,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,1
17292,hepatotoxicity,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,1
17293,nephrotoxicity,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,1
17302,nephrotoxicity,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,1
17303,renal toxicity,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,1
17304,Hepatotoxicity,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,1
17346,sparteine,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0
17356,sparteine,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,0
17369,prostate cancer,Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.,3461217_0,1
17384,prostate cancer,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,1
17419,neurotoxicity,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,1
17420,deferoxamine,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,0
17421,neurotoxicity,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,1
17422,deferoxamine,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,0
17423,deferoxamine,"When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic.",3503576_3,0
17425,deferoxamine,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,0
17429,deferoxamine,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0
17430,deferoxamine,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0
17431,ototoxicity,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,1
17432,deferoxamine,"Based on these data, a plan of management was developed that allows effective yet safe administration of deferoxamine.",3503576_7,0
17435,deferoxamine,Moderate abnormalities require a reduction of deferoxamine to 25 mg/kg per dose with careful monitoring.,3503576_10,0
17444,Nephrotoxicity,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,1
17447,Ototoxicity,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,1
17457,ototoxicity,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,1
17464,rheumatoid arthritis,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,1
17465,rheumatoid arthritis,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,1
17486,vasospasm,Intense vasospasm with threatened gangrene arose in the arm used for the infusion.,3564823_3,1
17488,vasospasm,"Since the cranial condition precluded use of more usual methods, lidocaine was given intra-arterially, with careful cardiovascular monitoring, to counteract the vasospasm.",3564823_4,1
17504,cefonicid,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,0
17505,cefazedone,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,0
17514,cefonicid,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,0
17515,cefazedone,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,0
17518,cefonicid,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,0
17519,cefazedone,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,0
17523,cefonicid,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,0
17532,cefonicid,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,0
17533,cefazedone,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,0
17539,renal damage,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,1
17548,nephrotoxicity,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,1
17572,renal damage,It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage.,3653576_8,1
17580,paracetamol,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,0
17588,paracetamol,"In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market.",3670965_7,0
17618,bromocriptine,Postpartum psychosis induced by bromocriptine.,3686155_0,0
17620,bromocriptine,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,0
17621,Bromocriptine,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,0
17625,bromocriptine,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,0
17643,cyclosporine,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,0
17646,renal toxicity,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,1
17653,ketoconazole,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,0
17657,nephrotoxicity,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,1
17686,Allergic reaction,Allergic reaction to 5-fluorouracil infusion.,3719553_0,1
17687,5-fluorouracil,Allergic reaction to 5-fluorouracil infusion.,3719553_0,0
17688,allergic reaction,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,1
17689,5-fluorouracil,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,0
17695,allergic reaction,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,1
17699,cardiac arrhythmias,It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.,3732088_1,1
17705,amiloride,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,0
17708,amiloride,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,0
17712,amiloride,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,0
17728,rheumatoid arthritis,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,1
17730,rheumatoid arthritis,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,1
17748,trihexyphenidyl,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,0
17751,trihexyphenidyl,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,0
17752,sinus bradycardia,"The patient developed, paradoxically, sinus bradycardia.",3769769_2,1
17753,trihexyphenidyl,The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs.,3769769_3,0
17762,carcinogenesis,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,1
17770,carcinogenesis,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,1
17778,akinetic,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,1
17780,akinetic,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,1
17794,rhabdomyolysis,A case of massive rhabdomyolysis following molindone administration.,3782049_0,1
17796,Rhabdomyolysis,Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop.,3782049_1,1
17800,rhabdomyolysis,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,1
17801,rhabdomyolysis,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,1
17818,renal dysfunction,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,1
17847,acute lymphoblastic leukemia,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,1
17864,mucositis,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,1
17868,acute lymphoblastic leukemia,High-dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia.,3856631_7,1
17871,etoposide,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,0
17874,etoposide,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,0
17889,nephrotoxicity,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,1
17890,ototoxicity,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,1
17892,nephrotoxicity,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,1
17893,ototoxicity,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,1
17894,aminoglycoside,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,0
17896,nephrotoxicity,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,1
17898,amikacin,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,0
17900,amikacin,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,0
17902,nephrotoxicity,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,1
17906,creatinine,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0
17907,creatinine,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0
17925,nephrotoxicity,"When the parameters were examined individually, duration of therapy and total AUC correlated significantly (P less than .05) with nephrotoxicity.",3950060_5,1
17945,Cardiac toxicity,Cardiac toxicity of 5-fluorouracil.,3952818_0,1
17946,5-fluorouracil,Cardiac toxicity of 5-fluorouracil.,3952818_0,0
17950,5-fluorouracil,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,0
17955,coronary spasm,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,1
17956,cardiotoxicity,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,1
17980,Hepatotoxicity,Hepatotoxicity of amiodarone.,3962737_0,1
17983,hepatotoxicity,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,1
17985,hepatic injury,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,1
17990,carcinogenesis,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,1
17997,prostate cancer,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,1
18001,prostate cancer,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,1
18002,prostate cancer,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,1
18007,prostate cancer,Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer.,3969369_6,1
18008,rheumatoid arthritis,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,1
18011,rheumatoid arthritis,Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis.,3970039_1,1
18012,cyclophosphamide,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,0
18025,Cyclophosphamide,Cyclophosphamide therapy increases the risk of carcinoma of the bladder.,3970039_7,0
18026,rheumatoid arthritis,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,1
18028,cyclophosphamide,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,0
18029,rheumatoid arthritis,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,1
18032,rheumatoid arthritis,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,1
18053,peripheral neuropathy,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,1
18069,sinus bradycardia,Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.,4008111_2,1
18083,bupivacaine,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0
18124,paracetamol,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,0
18128,paracetamol,Groups of male and female inbred Leeds strain rats were fed diets containing either 0.5% or 1.0% paracetamol by weight for up to 18 months.,4090988_2,0
18139,paracetamol,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,0
18145,hepatic injury,Patterns of hepatic injury induced by methyldopa.,424937_0,1
18146,liver disease,Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977.,424937_1,1
18153,hepatic injury,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,1
18170,Suxamethonium,Suxamethonium infusion rate and observed fasciculations.,435349_0,0
18172,Suxamethonium,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,0
18189,metoclopramide,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,0
18197,dystonia,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,1
18203,liver damage,Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.,4812392_4,1
18218,hepatotoxicity,We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.,48362_5,1
18229,platelet aggregation,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,1
18256,propranolol,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,0
18260,propranolol,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,0
18269,propranolol,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,0
18274,propranolol,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,0
18278,propranolol,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,0
18285,propranolol,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,0
18287,propranolol,No corneal disease is known to have occurred in the propranolol group.,6115999_7,0
18290,propranolol,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,0
18295,myoclonic jerks,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,1
18298,myoclonic jerks,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,1
18300,5-hydroxytryptophan,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,0
18307,myoclonic jerks,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,1
18331,sulphasalazine,Possible teratogenicity of sulphasalazine.,6133211_0,0
18333,sulphasalazine,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,0
18346,sulphasalazine,"Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.",6133211_6,0
18365,creatinine,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0
18379,Thrombotic microangiopathy,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,1
18383,thrombotic microangiopathy,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,1
18386,cisplatin,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,0
18389,thrombotic,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,1
18390,hemolytic-uremic syndrome,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,1
18398,thrombotic microangiopathy,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,1
18403,bone marrow suppression,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,1
18404,cardiac hypertrophy,Development of isoproterenol-induced cardiac hypertrophy.,6203632_0,1
18405,cardiac hypertrophy,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,1
18448,rheumatoid arthritis,Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.,6216862_0,1
18452,rheumatoid arthritis,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,1
18457,rheumatoid arthritis,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,1
18497,milk fever,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,1
18500,milk fever,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,1
18509,milk fever,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,1
18510,milk fever,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,1
18512,milk fever,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,1
18522,Peripheral neuropathy,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,1
18525,autonomic neuropathy,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,1
18545,salmon calcitonin,"injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system, were investigated in male rats.",6293644_2,0
18586,hyperammonemia,Modification of drug action by hyperammonemia.,6323692_0,1
18588,ammonium acetate,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,0
18595,hyperammonemia,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,1
18600,liver disease,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,1
18618,hyperammonemia,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,1
18640,dry mouth,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,1
18648,propranolol,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,0
18653,propranolol,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,0
18659,propranolol,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,0
18662,propranolol,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0
18663,propranolol,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0
18669,MESNA,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,0
18673,MESNA,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0
18675,ifosfamide,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0
18680,MESNA,"MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.",6402369_2,0
18685,MESNA,In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions (total 31%).,6402369_4,0
18696,MESNA,There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.,6402369_7,0
18699,MESNA,"Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include IF, simplifies the treatment and provides optimum protection for the urinary epithelium.",6402369_8,0
18703,MESNA,Protection with oral MESNA is particularly suitable for outpatients.,6402369_9,0
18705,carbamazepine,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,0
18707,carbamazepine,"Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.",6415512_1,0
18711,carbamazepine,"When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.",6415512_2,0
18719,picrotoxin,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0
18722,bicuculline,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0
18729,picrotoxin,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0
18730,bicuculline,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0
18759,creatinine,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,0
18764,glycopyrrolate,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0
18765,suxamethonium,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0
18766,glycopyrrolate,The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v.,6466532_2,0
18769,suxamethonium,"immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied.",6466532_3,0
18771,glycopyrrolate,A control group was included for comparison with the lower dose range of glycopyrrolate and atropine.,6466532_4,0
18777,glycopyrrolate,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0
18780,suxamethonium,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0
18787,liver disease,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,1
18829,polyethylene glycol 400,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,0
18832,polyethylene glycol 400,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0
18836,adriamycin,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0
18865,thromboembolic,"Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.",6615052_2,1
18870,thromboembolic,"The 20 deaths, 52 hemorrhagic and thromboembolic complications, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder.",6615052_5,1
18874,platelet aggregation,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,1
18887,sodium citrate,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0
18902,ventricular tachycardia,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,1
18908,ventricular tachycardia,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,1
18910,ventricular tachycardia,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,1
18911,cardiac arrest,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,1
18932,adriamycin,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,0
18934,Adriamycin,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,0
18944,Adriamycin,"The beneficial effect of Adriamycin appears obvious and might be related to the drug itself, the early and repeated instillations after TUR, or both.",6640832_13,0
19042,Renal papillary necrosis,Renal papillary necrosis due to naproxen.,6699841_0,1
19043,rheumatoid arthritis,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,1
19048,renal papillary necrosis,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,1
19056,renal toxicity,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,1
19059,metoclopramide,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,0
19060,metoclopramide,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,0
19062,metoclopramide,"When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.",6727060_3,0
19064,aminoglycoside,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,0
19080,aminoglycosides,All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium.,6728084_6,0
19088,aminoglycosides,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,0
19133,visual loss,The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered.,6747681_11,1
19134,Cardiotoxic,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,1
19136,adriamycin,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0
19138,adriamycin,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0
19141,adriamycin,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,0
19145,adriamycin,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,0
19146,adriamycin,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,0
19152,autonomic neuropathy,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,1
19153,autonomic neuropathy,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,1
19157,autonomic neuropathy,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,1
19160,autonomic neuropathy,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,1
19162,autonomic neuropathy,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,1
19191,cycloheximide,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0
19193,cycloheximide,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0
19256,carbachol,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,0
19261,carbachol,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,0
19264,carbachol,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,0
19266,carbachol,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,0
19271,carbachol,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,0
19274,carbachol,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,0
19279,cardiac arrhythmias,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,1
19320,fulminant hepatic failure,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,1
19323,fulminant hepatic failure,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,1
19325,fulminant hepatic failure,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,1
19329,aspartate,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,0
19334,creatinine,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,0
19335,creatinine,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0
19359,Visual loss,"Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.",7059267_2,1
19361,visual loss,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,1
19375,nephrotic,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,1
19381,nephrotic,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,1
19388,nephrotic,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,1
19393,nephrotic,It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism.,7066357_12,1
19395,aplastic anemia,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,1
19399,aplastic anemia,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,1
19401,aplastic anemia,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,1
19404,aplastic anemia,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,1
19432,thiopentone,Midazolam compared with thiopentone as an induction agent.,7102237_0,0
19435,thiopentone,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0
19437,apnoea,"Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.",7102237_2,1
19438,thiopentone,"On the whole, the differences between midazolam and thiopentone had no apparent clinical consequences.",7102237_3,0
19455,bupivacaine,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0
19458,bupivacaine,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,0
19483,bupivacaine,"Neurologic effects of subarachnoid administration of 2-chloroprocaine-CE, bupivacaine, and low pH normal saline in dogs.",7199841_0,0
19486,neurotoxicity,The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated.,7199841_2,1
19488,bupivacaine,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,0
19493,bupivacaine,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,0
19500,bupivacaine,"The spinal cords of the animals that received bupivacaine, low pH normal saline (pH 3.0), or normal saline did not show abnormal findings.",7199841_7,0
19504,ventricular tachycardia,Procainamide-induced polymorphous ventricular tachycardia.,7234705_0,1
19506,ventricular tachycardia,Seven cases of procainamide-induced polymorphous ventricular tachycardia are presented.,7234705_1,1
19507,ventricular tachycardia,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,1
19509,procainamide,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,0
19510,ventricular tachycardia,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,1
19511,procainamide,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,0
19515,ventricular tachycardia,These patients had Q-T prolongation and recurrent syncope due to polymorphous ventricular tachycardia.,7234705_4,1
19519,procainamide,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,0
19520,ventricular tachycardia,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,1
19521,procainamide,These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.,7234705_8,0
19524,ventricular tachycardia,These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.,7234705_8,1
19537,aplastic anemia,Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.,7263204_0,1
19539,aplastic anemia,"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.",7263204_1,1
19541,aplastic anemia,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,1
19545,aplastic anemia,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,1
19558,busulfan,"In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites, periodic urinary cytology is suggested in patients on long-term therapy.",7269015_4,0
19565,Adriamycin,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,0
19581,myocardial damage,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,1
19587,ventricular tachycardia,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,1
19589,ventricular tachycardia,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,1
19596,ventricular tachycardia,Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia.,7292072_3,1
19597,ventricular tachycardia,Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia.,7292072_3,1
19600,fulminant hepatic failure,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,1
19604,fulminant hepatic failure,Cerebral edema may complicate the course of fulminant hepatic failure.,7337133_1,1
19605,fulminant hepatic failure,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,1
19611,sodium nitroprusside,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0
19612,saralasin,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0
19614,sodium nitroprusside,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,0
19617,saralasin,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,0
19630,saralasin,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,0
19631,saralasin,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,0
19633,sexual dysfunction,Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.,7416947_0,1
19655,nephrotoxicity,Clinical nephrotoxicity of tobramycin and gentamicin.,7420681_0,1
19657,aminoglycoside,Nearly 3.2 million people in this country receive aminoglycoside antibiotics annually.,7420681_2,0
19658,ototoxicity,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,1
19659,nephrotoxicity,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,1
19675,endometrial cancer,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,1
19679,cardiotoxic,The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.,7423039_1,1
19680,adriamycin,The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.,7423039_1,0
19683,Adriamycin,Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture.,7423039_2,0
19702,Creatinine,"Creatinine clearance, maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long-term lithium for more than one year.",7437994_3,0
19717,Cardiac toxicity,Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.,7449470_1,1
19718,adriamycin,Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.,7449470_1,0
19723,cardiotoxicity,"A patient is reported who developed progressive cardiomyopathy two and one-half years after receiving 580 mg/m2 which apparently represents late, late cardiotoxicity.",7449470_3,1
19725,amiloride,Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.,7453952_0,0
19726,amiloride,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,0
19730,Amiloride,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,0
19732,amiloride,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,0
19737,amiloride,"In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.",7453952_6,0
19739,amiloride,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0
19741,amiloride,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0
19743,terbutaline,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,0
19746,terbutaline,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,0
19754,carbimazole,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,0
19762,carbimazole,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,0
19764,carbimazole,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,0
19766,carbimazole,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,0
19771,hepatotoxicity,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,1
19823,Nephrotoxicity,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,1
19832,rapamycin,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,0
19849,rapamycin,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,0
19853,rapamycin,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0
19860,carboplatin,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,0
19861,Carboplatin,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,0
19865,carboplatin,We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.,7565311_2,0
19872,paramethasone,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,0
19879,paramethasone,"In the two patients, skin and ELISA tests with paramethasone were negative, as was the prick test with each of its excipients.",7582165_5,0
19887,paramethasone,These results suggest that paramethasone caused pseudoallergic reactions in our patients.,7582165_8,0
19889,paramethasone,"Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.",7582165_9,0
19892,paramethasone,"To our knowledge, this is the first report of a pseudo-allergy caused by paramethasone.",7582165_11,0
19912,platelet aggregation,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,1
19956,etoposide,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,0
19961,folinic acid,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,0
19964,folinic acid,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,0
19965,bone marrow suppression,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,1
19970,folinic acid,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0
19983,myelosuppression,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,1
19985,folinic acid,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,0
19996,hepatic injury,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,1
20032,cardiac arrhythmias,Seizures and cardiac arrhythmias have complicated its use in adult patients.,7651879_2,1
20077,malondialdehyde,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,0
20083,malondialdehyde,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,0
20086,malondialdehyde,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,0
20091,malondialdehyde,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0
20095,nitroprusside,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0
20098,malondialdehyde,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0
20099,malondialdehyde,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,0
20106,renal toxicity,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,1
20124,renal toxicity,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,1
20175,dobutamine,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0
20180,renal dysfunction,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,1
20196,creatinine,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,0
20197,blood urea nitrogen,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,0
20201,creatinine,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,0
20206,creatinine,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,0
20209,renal dysfunction,CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.,7791169_8,1
20243,aggressive behavior,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,1
20255,ouabain,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,0
20263,ouabain,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,0
20267,ouabain,"Because the protocol was long and involved interventions which might affect the determinations, we also studied in nine patients using an identical protocol except that ouabain administration was omitted.",783197_4,0
20270,ouabain,"Left ventricular end-diastolic pressure and left ventricular end-diastolic volume fell in each patient given ouabain, even though they were initially elevated in only two patients.",783197_5,0
20274,ouabain,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,0
20281,ouabain,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,0
20283,ouabain,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,0
20288,ouabain,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,0
20343,5-fluorouracil,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0
20344,folinic acid,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0
20348,etoposide,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0
20349,5-fluorouracil,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0
20350,folinic acid,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0
20354,5-fluorouracil,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,0
20355,folinic acid,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,0
20357,5-fluorouracil,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0
20358,folinic acid,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0
20359,folinic acid,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0
20361,neurotoxicity,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,1
20363,5-fluorouracil,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0
20369,carbamazepine,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,0
20372,Carbamazepine,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,0
20374,extrapyramidal symptoms,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,1
20388,Bupivacaine,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0
20389,bupivacaine,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0
20393,bupivacaine,The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine.,7880714_6,0
20418,octreotide,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,0
20420,Octreotide,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,0
20421,octreotide,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,0
20436,octreotide,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,0
20495,methylprednisolone,The patient was treated with methylprednisolone and gradually improved.,7919560_4,0
20498,allergic reaction,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,1
20564,platelet aggregation,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,1
20611,coniine,Effect of coniine on the developing chick embryo.,8073369_0,0
20612,Coniine,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,0
20617,coniine,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,0
20620,coniine,The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick.,8073369_4,0
20621,coniine,"Concentrations of coniine and nicotine sulfate were 0.015%, 0.03%, 0.075%, 0.15%, 0.75%, 1.5%, 3%, and 6% and 1%, 5%, and 10%, respectively.",8073369_5,0
20623,coniine,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,0
20624,coniine,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,0
20629,coniine,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,0
20634,allergic reactions,Immediate allergic reactions to amoxicillin.,8092427_0,1
20635,allergic reactions,A large group of patients with suspected allergic reactions to beta-lactam antibiotics was evaluated.,8092427_1,1
20671,allergic reaction,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,1
20679,acute myocardial infarction,Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.,809711_0,1
20681,acute myocardial infarction,"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.",809711_1,1
20698,acute myocardial infarction,Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.,809711_7,1
20701,parkinsonian,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,1
20709,propranolol,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0
20712,parkinsonian,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,1
20713,yohimbine,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,0
20718,neurotoxicity,Hallucinations and ifosfamide-induced neurotoxicity.,8111719_0,1
20719,neurotoxicity,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,1
20721,ifosfamide,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,0
20723,ifosfamide,All patients were receiving high-dose ifosfamide as part of their bone marrow transplant procedure.,8111719_4,0
20726,neurotoxicity,CONCLUSIONS: Hallucinations may be the sole or first manifestation of neurotoxicity.,8111719_7,1
20728,neurotoxicity,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,1
20746,bepridil,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,0
20749,bupivacaine,dose of bupivacaine.,8231633_3,0
20755,bupivacaine,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0
20757,bepridil,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0
20768,rheumatoid arthritis,Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.,8267029_0,1
20769,rheumatoid arthritis,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,1
20780,cyclophosphamide,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,0
20801,Hyperalgesia,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,1
20805,hyperalgesia,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,1
20807,hyperalgesia,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,1
20858,daunorubicin,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,0
20863,daunorubicin,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,0
20872,cardiotoxicity,There was no evidence of cardiotoxicity.,8305357_10,1
20873,daunorubicin,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,0
20883,losartan,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0
20931,penile pain,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,1
20934,penile pain,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,1
20938,penile pain,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,1
20945,penile pain,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,1
20947,penile pain,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,1
20948,penile pain,"From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication, which can be overcome by elevating the pH to a neutral level.",8386779_8,1
20970,Peripheral neuropathy,Peripheral neuropathy occurred in 12 patients and pancreatitis in six.,8387218_9,1
20975,oral contraceptives,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,0
20980,oral contraceptives,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,0
21033,cresyl violet,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,0
21076,octreotide,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,0
21083,octreotide,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,0
21086,octreotide,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,0
21088,octreotide,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,0
21091,octreotide,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,0
21093,octreotide,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,0
21097,motor disability,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,1
21142,rheumatoid arthritis,Apparent cure of rheumatoid arthritis by bone marrow transplantation.,8441146_0,1
21144,rheumatoid arthritis,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,1
21148,aplastic anemia,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,1
21160,ventricular tachycardia,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,1
21197,rhabdomyolysis,Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.,8492347_0,1
21205,nephrotoxicity,Ciprofloxacin-induced nephrotoxicity in patients with cancer.,8494478_0,1
21206,Nephrotoxicity,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,1
21209,creatinine,"Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.",8494478_3,0
21211,interstitial nephritis,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,1
21234,visual hallucinations,Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.,8546130_0,1
21235,chronic renal failure,Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.,8546130_0,1
21236,Visual hallucinations,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,1
21237,chronic renal failure,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,1
21238,visual hallucinations,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,1
21241,end-stage renal disease,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,1
21249,chronic renal failure,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,1
21274,vinorelbine,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,0
21279,vinorelbine,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,0
21296,neurotoxicity,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,1
21348,Thiopentone,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0
21350,propofol,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0
21352,propofol,This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia.,8595686_1,0
21355,propofol,"In a randomized, double-blind trial, 90 women were allocated to receive one of three treatments prior to induction of anaesthesia with propofol.",8595686_2,0
21358,thiopentone,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,0
21361,propofol,Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1).,8595686_4,0
21380,propofol,"Assessing their overall satisfaction, 89.7% would choose propofol anaesthesia again.",8595686_9,0
21381,propofol,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0
21383,thiopentone,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0
21393,cardiotoxicity,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,1
21404,cardiac toxicity,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,1
21406,ventricular arrhythmias,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,1
21418,cardiotoxicity,"The incidence of doxorubicin-induced cardiotoxicity is high and increases with follow-up, irrespective of cumulative dose.",8600333_9,1
21422,cardiotoxicity,The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity.,8600333_11,1
21496,paclitaxel,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,0
21498,Paclitaxel,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,0
21502,breast carcinoma,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,1
21504,paclitaxel,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,0
21510,paclitaxel,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,0
21516,Paclitaxel,Paclitaxel 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication.,8643966_7,0
21524,polyneuropathy,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,1
21525,polyneuropathy,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,1
21531,Paclitaxel,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,0
21537,paclitaxel,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0
21540,paclitaxel,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0
21543,paclitaxel,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0
21544,cisplatin,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0
21549,paclitaxel,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,0
21555,ovarian cancer,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,1
21557,paclitaxel,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0
21558,cisplatin,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0
21567,paclitaxel,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0
21569,cisplatin,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0
21570,paclitaxel,"The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.",8643971_8,0
21573,paclitaxel,"With paclitaxel doses of 200 mg/m2 and higher, granulocyte colony-stimulating factor 5 micrograms/kg/d is given (days 4 through 12).",8643971_10,0
21588,paclitaxel,Results thus far suggest no dose-response effect for paclitaxel doses above 200 mg/m2.,8643971_19,0
21589,Paclitaxel,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,0
21590,carboplatin,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,0
21592,ovarian cancer,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,1
21595,paclitaxel,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0
21598,carboplatin,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0
21599,ovarian cancer,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,1
21600,paclitaxel,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0
21602,carboplatin,The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.,8643973_2,0
21605,carboplatin,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0
21606,paclitaxel,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0
21610,myelosuppression,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,1
21611,Neurotoxicity,Neurotoxicity was largely moderate.,8643973_6,1
21614,paclitaxel,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0
21617,carboplatin,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0
21621,paclitaxel,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0
21623,carboplatin,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0
21624,propranolol,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,0
21628,propranolol,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,0
21632,dystonia,"Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not.",8649546_3,1
21641,methylprednisolone,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,0
21675,chronic renal failure,Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.,8669433_0,1
21679,chronic renal failure,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,1
21680,end-stage renal disease,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,1
21689,chronic renal failure,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,1
21697,mesna,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,0
21700,ifosfamide,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0
21701,mesna,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0
21703,Mesna,"Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.",8677458_2,0
21707,mesna,The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access.,8677458_3,0
21712,mesna,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0
21713,mesna,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0
21716,mesna,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,0
21719,ifosfamide,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,0
21723,allergic reactions,Other symptoms of allergic reactions were not clinically detectable.,8682684_5,1
21729,lignocaine,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,0
21730,lignocaine,"Fifty-four patients, aged 27-90 years, who were given lignocaine 5% in 6.8% glucose solution for spinal anaesthesia were studied.",8686832_1,0
21737,lignocaine,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,0
21742,diabetic nephropathy,Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.,8690168_0,1
21747,streptozotocin,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,0
21818,tacrolimus,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,0
21822,tacrolimus,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,0
21826,dipyridamole,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0
21836,apnoea,Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.,871943_1,1
21883,renal toxicity,Effect of some anticancer drugs and combined chemotherapy on renal toxicity.,8739323_0,1
21887,5-fluorouracil,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
21889,cyclophosphamide,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
21897,creatinine,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0
21898,creatinine,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0
21901,creatinine,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0
21902,creatinine,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0
21906,creatinine,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0
21907,creatinine,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0
21911,creatinine,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0
21912,creatinine,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0
21925,nephrotoxicity,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,1
21952,liver injury,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,1
21973,liver damage,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,1
21982,hepatic damage,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,1
21992,cognitive deficits,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,1
22001,cognitive deficits,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,1
22010,paroxetine,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,0
22037,ventricular arrhythmias,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,1
22046,tacrolimus,Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.,8829025_0,0
22049,tacrolimus,The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996.,8829025_1,0
22050,tacrolimus,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,0
22053,creatinine,Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months.,8829025_4,0
22054,nephrotoxicity,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,1
22056,tacrolimus,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,0
22143,Venlafaxine,Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine.,8888541_3,0
22146,venlafaxine,He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.,8888541_5,0
22147,myoclonic jerks,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,1
22159,rhabdomyolysis,The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of rhabdomyolysis.,8888541_12,1
22164,hemolytic uremic syndrome,Late recovery of renal function in a woman with the hemolytic uremic syndrome.,891050_0,1
22165,hemolytic uremic syndrome,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,1
22167,oral contraceptives,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,0
22169,dipyridamole,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,0
22176,Cyclophosphamide,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,0
22177,bladder cancer,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,1
22179,cyclophosphamide,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,0
22181,cyclophosphamide,MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.,8911359_2,0
22182,bladder cancer,MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.,8911359_2,1
22188,Cyclophosphamide,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,0
22230,hepatic damage,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,1
22231,hyperammonemia,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,1
22236,allergic reaction,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,1
22240,cardiac arrest,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,1
22242,cardiac arrest,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,1
22244,allergic reaction,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,1
22245,bradykinin,Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_0,0
22250,bradykinin,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,0
22255,dextran,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,0
22260,dextran,"Phenylephrine infusion increased arterial pressure, arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups.",8955532_4,0
22263,bradykinin,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,0
22271,glycinamide ribonucleotide,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,0
22288,mucositis,Thrombocytopenia and mucositis were the major toxicities.,8958188_6,1
22300,benzoylecgonine,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,0
22304,rhabdomyolysis,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,1
22306,sensorineural hearing loss,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,1
22309,sensorineural hearing loss,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,1
22317,Ototoxicity,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,1
22320,aminoglycosides,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,0
22359,major depression,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,1
22360,venlafaxine,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,0
22362,venlafaxine,"After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.",9034419_3,0
22364,venlafaxine,"She was admitted to the medical intensive care unit, venlafaxine was discontinued, and no further sequelae were seen.",9034419_4,0
22368,venlafaxine,"Based on nonoverdose pharmacokinetics and pharmacodynamics of venlafaxine and the potential risks of available interventions, no emergent therapy was instituted.",9034419_6,0
22396,acute liver failure,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,1
22399,acute liver failure,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,1
22429,adriamycin,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,0
22452,cardiotoxic,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,1
22453,adriamycin,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0
22466,haemodilution,Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.,9088814_0,1
22470,haemodilution,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,1
22475,haemodilution,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,1
22477,haemodilution,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,1
22478,Haemodilution,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,1
22480,dextran,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,0
22503,haemodilution,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,1
22505,hyperprolactinemia,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,1
22508,hyperprolactinemia,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,1
22511,hyperprolactinemia,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,1
22554,pilocarpine-,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,0
22565,"pilocarpine-,","Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,0
22601,pilocarpine-,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,0
22617,nephrotic,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,1
22632,risperidone,Neuroleptic malignant syndrome with risperidone.,9165568_0,0
22635,Risperidone,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,0
22639,extrapyramidal symptoms,The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.,9165568_3,1
22640,risperidone,The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.,9165568_3,0
22641,extrapyramidal symptoms,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,1
22645,risperidone,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,0
22646,risperidone,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0
22648,bromocriptine,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0
22651,risperidone,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,0
22654,sumatriptan,The site of common side effects of sumatriptan.,9195768_0,0
22655,sumatriptan,"Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.",9195768_1,0
22659,amikacin,Macula toxicity after intravitreal amikacin.,9199746_0,0
22660,aminoglycosides,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,0
22663,amikacin,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,0
22664,amikacin,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,0
22688,propranolol,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0
22692,propranolol,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,0
22695,propranolol,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,0
22718,breast carcinoma,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,1
22719,aspartate,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,0
22724,azidothymidine,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,0
22779,17beta-estradiol,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,0
22860,dilated cardiomyopathy,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,1
22862,dilated cardiomyopathy,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,1
22874,parkinsonian,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,1
22909,liver disease,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,1
22913,hepatotoxicity,Limited studies in animals indicate potential hepatotoxicity of some of these compounds.,9284778_2,1
22914,liver disease,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,1
22916,"1,1-dichloro-2,2,2-trifluoroethane","We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0
22917,"1-chloro-1,2,2,2-tetrafluoroethane","We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0
22919,"1-bromo-1-chloro-2,2,2-trifluoroethane","Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,0
22920,hepatotoxicity,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,1
22921,liver disease,We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.,9284778_6,1
22940,liver injury,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,1
22942,hepatotoxicity,"Although the exact mechanism of hepatotoxicity of these agents is not known, the results suggest that trifluoroacetyl-altered liver proteins are involved.",9284778_13,1
22946,danazol,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,0
22948,danazol,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,0
22956,temporal lobe epilepsy,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,1
22963,temporal lobe epilepsy,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,1
22972,brain damage,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,1
23028,ventricular tachycardia,Clarithromycin-induced ventricular tachycardia.,9326871_0,1
23036,Cardiotoxicity,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,1
23055,low sexual desire,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,1
23061,low sexual desire,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,1
23066,bromocriptine,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,0
23067,hyperprolactinemia,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,1
23074,low sexual desire,"Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.",9334596_13,1
23077,prolactinoma,Only 1 prolactinoma was discovered.,9334596_16,1
23079,Bromocriptine,Bromocriptine was definitely effective in cases with prolactin greater than 35 ng./ml.,9334596_19,0
23085,low sexual desire,We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.,9334596_24,1
23087,low sexual desire,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",9334596_25,1
23089,risperidone,Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.,9351491_0,0
23091,Risperidone,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,0
23095,risperidone,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,0
23097,psychotic symptoms,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,1
23099,risperidone,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0
23107,risperidone,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0
23108,risperidone,Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses.,9351491_4,0
23111,risperidone,There was no significant difference between occupancy levels obtained with haloperidol or risperidone.,9351491_5,0
23113,risperidone,Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.,9351491_6,0
23115,risperidone,"Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.",9351491_7,0
23119,breast cancer,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,1
23120,mitoxantrone,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,0
23126,breast cancer,"For previously treated advanced breast cancer, there is no standard second-line therapy.",9390208_1,1
23129,mitoxantrone,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0
23130,5-fluorouracil,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0
23134,breast cancer,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,1
23135,mitoxantrone,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,0
23141,anthracycline,Seven patients had been treated with anthracycline.,9390208_6,0
23145,mitoxantrone,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,0
23153,cardiotoxicity,Major toxicities were cardiotoxicity and leukopenia.,9390208_15,1
23156,breast cancer,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,1
23158,aplastic anemia,Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.,9401499_0,1
23159,aplastic anemia,"In this study, three Chinese patients with ticlopidine-induced aplastic anemia were reported and another 13 patients in the English literature were reviewed.",9401499_1,1
23163,ticlopidine,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,0
23165,bone marrow suppression,There seemed to be no direct correlation between the dose or duration used and the severity of bone marrow suppression.,9401499_6,1
23166,aplastic anemia,Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.,9401499_7,1
23273,3-aminopropyl-diethoxy-methyl-phosphinic acid,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
23278,5-hydroxytryptamine4,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
23279,2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
23281,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
23313,rheumatoid arthritis,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,1
23352,sensorineural hearing loss,"Up until now, the only factor studied has been the effect of the diameter of the spinal needle on post-operative sensorineural hearing loss.",9522143_2,1
23355,prilocaine,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,0
23356,bupivacaine,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,0
23357,prilocaine,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0
23359,bupivacaine,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0
23362,prilocaine,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0
23363,bupivacaine,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0
23367,bupivacaine,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,0
23371,bupivacaine,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,0
23386,prilocaine,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0
23387,bupivacaine,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0
23390,bupivacaine,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,0
23392,Prilocaine,Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine.,9523805_3,0
23394,prilocaine,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0
23395,bupivacaine,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0
23401,prilocaine,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0
23402,bupivacaine,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0
23409,prilocaine,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0
23410,bupivacaine,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0
23411,prilocaine,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0
23412,bupivacaine,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0
23413,Prilocaine,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,0
23416,methylprednisolone,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,0
23428,methylprednisolone,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,0
23444,Cisapride,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,0
23453,cisapride,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,0
23457,cisapride,"After discontinuing cisapride, the QT interval returned to normal and symptoms did not recur.",9545159_5,0
23459,cisapride,"We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4, including diltiazem.",9545159_6,0
23463,parkinsonian,Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.,9549528_0,1
23468,parkinsonian,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,1
23475,parkinsonian,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,1
23486,levofloxacin,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,0
23488,levofloxacin,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,0
23517,levofloxacin,Adverse events considered to be related to levofloxacin administration were reported by 29 patients (9%).,9564988_12,0
23520,levofloxacin,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,0
23522,breast cancer,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,1
23524,breast cancer,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,1
23525,breast cancer,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,1
23526,endometrial cancer,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,1
23527,breast cancer,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,1
23529,endometrial cancer,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,1
23530,breast cancer,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,1
23531,breast cancer,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,1
23534,endometrial cancer,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,1
23544,endometrial cancer,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,1
23547,endometrial cancer,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,1
23548,endometrial cancer,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,1
23549,breast cancer,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,1
23552,breast cancer,Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer.,9579567_10,1
23555,breast cancer,Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.,9579567_12,1
23558,breast cancer,A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.,9579567_13,1
23560,cardiac arrest,Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.,9587734_0,1
23561,cardiac arrest,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,1
23563,suxamethonium,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,0
23565,suxamethonium,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,0
23566,cardiac arrest,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,1
23572,suxamethonium,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,0
23573,suxamethonium,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,0
23575,autoimmune hemolytic anemia,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,1
23578,autoimmune hemolytic anemia,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,1
23598,"5,7-dichlorokynurenic acid","5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,0
23613,Carboplatin,Carboplatin toxic effects on the peripheral nervous system of the rat.,9636837_0,0
23615,carboplatin,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0
23617,cisplatin,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0
23625,Neurotoxicity,"Neurotoxicity was assessed for behavioral (tail-flick test), neurophysiological (nerve conduction velocity in the tail nerve), morphological, morphometrical and analytical effects.",9636837_4,1
23632,neurotoxicity,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,1
23646,neurotoxicity,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,1
23651,drug abuse,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,1
23674,5-hydroxytryptophan,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,0
23677,locomotor hyperactivity,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,1
23694,cisapride,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,0
23701,cisapride,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,0
23710,cisapride,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,0
23712,cisapride,RESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups.,9669632_4,0
23718,cisapride,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0
23723,cisapride,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0
23730,cisapride,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0
23743,cisapride,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,0
23747,cisapride,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0
23750,cisapride,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0
23753,Cisapride,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,0
23756,breast cancer,Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.,9672273_0,1
23760,breast cancer,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,1
23762,endometrial cancer,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,1
23767,breast cancer,"METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy.",9672273_4,1
23771,breast cancer,The primary endpoints are the occurrence of and deaths from breast cancer.,9672273_9,1
23774,breast cancer,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,1
23775,breast cancer,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,1
23778,breast cancer,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,1
23780,breast cancer,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,1
23786,breast cancer,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_16,1
23789,breast cancer,There were no deaths from breast cancer recorded in women in the study.,9672273_18,1
23790,pethidine,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,0
23791,pethidine,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,0
23794,pethidine,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,0
23801,pethidine,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0
23803,pethidine,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0
23805,pethidine,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,0
23840,tacrolimus,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,0
23848,primary pulmonary hypertension,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,1
23850,appetite suppressants,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,0
23851,Primary pulmonary hypertension,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,1
23855,appetite suppressants,The importance of this association was evaluated in Belgium while this country still had no restriction on the prescription of appetite suppressants.,9727773_2,0
23856,primary pulmonary hypertension,Thirty-five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months (1992-1994) in Belgium.,9727773_3,1
23859,appetite-suppressants,Exposure to appetite-suppressants was assessed on the basis of hospital records and standardized interview.,9727773_4,0
23862,appetite suppressants,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,0
23864,appetite suppressants,"Five patients died before the interview, all of them had taken appetite suppressants.",9727773_6,0
23865,primary pulmonary hypertension,"In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.",9727773_7,1
23866,appetite suppressants,"In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.",9727773_7,0
23868,appetite suppressants,"The patients who had been exposed to appetite suppressants tended to be on average more severely ill, and to have a shorter median delay between onset of symptoms and diagnosis.",9727773_8,0
23871,appetite suppressants,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,0
23872,primary pulmonary hypertension,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,1
23873,appetite suppressants,Intake of appetite suppressants may accelerate the progression of the disease.,9727773_10,0
23875,carbamazepine,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0
23876,vigabatrin,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0
23877,Carbamazepine,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,0
23878,vigabatrin,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,0
23880,carbamazepine,"Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on.",9746003_2,0
23882,Vigabatrin,Vigabatrin was also used in the treatment of two children.,9746003_3,0
23884,carbamazepine,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,0
23885,myoclonic jerks,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,1
23886,carbamazepine,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,0
23887,vigabatrin,Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment.,9746003_5,0
23912,carbamazepine,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,0
23939,extrapyramidal symptoms,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
23944,orthostatic hypotension,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
23947,sexual dysfunction,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
23954,sexual dysfunction,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,1
23960,ischemic stroke,The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.,9799166_1,1
24038,acetylsalicylic acid,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0
24039,dipyridamole,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0
24040,myocardial injury,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,1
24041,myocardial injury,A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.,983936_1,1
24043,acute myocardial infarction,A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.,983936_1,1
24055,acetylsalicylic acid,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0
24056,dipyridamole,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0
24062,Acetylsalicylic acid,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0
24063,dipyridamole,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0
24070,cardiotoxic,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,1
24073,cardiotoxicity,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,1
24085,cardiotoxic,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,1
24089,cardiotoxic,The low-grade cardiotoxic changes were enhanced by the additional doxorubicin treatment.,9848575_7,1
24092,cardiotoxicity,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,1
24093,cardiotoxicity,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,1
24097,tacrolimus,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,0
24102,tacrolimus,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,0
24129,creatinine,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,0
24199,valvular heart disease,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,1
24216,mitral regurgitation,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,1
24218,mitral regurgitation,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,1
24220,valvular heart disease,"RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.",9867728_8,1
24225,valvular heart disease,CONCLUSION: Users of diet medications are at risk for valvular heart disease.,9867728_11,1
24231,3alpha-tropyl 2-(p-bromophenyl)propionate,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0
24285,creatinine,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,0
24287,nephrotoxicity,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,1
24301,propranolol,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0
24302,hexamethonium,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0
24303,carbachol,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0
24313,nephrotoxicity,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,1
24354,adriamycin,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,0
